TWI472533B - 新穎化合物 - Google Patents
新穎化合物 Download PDFInfo
- Publication number
- TWI472533B TWI472533B TW99110332A TW99110332A TWI472533B TW I472533 B TWI472533 B TW I472533B TW 99110332 A TW99110332 A TW 99110332A TW 99110332 A TW99110332 A TW 99110332A TW I472533 B TWI472533 B TW I472533B
- Authority
- TW
- Taiwan
- Prior art keywords
- carbonyl
- naphtho
- hydroxy
- oxazol
- tetradecahydrocyclopenta
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 135
- 150000003839 salts Chemical class 0.000 claims description 65
- 239000000203 mixture Substances 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 50
- 239000003112 inhibitor Substances 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 12
- 208000006673 asthma Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
- 102000009410 Chemokine receptor Human genes 0.000 claims description 6
- 108050000299 Chemokine receptor Proteins 0.000 claims description 6
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 6
- 108091000080 Phosphotransferase Proteins 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000000812 cholinergic antagonist Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 102000020233 phosphotransferase Human genes 0.000 claims description 6
- 108060003345 Adrenergic Receptor Proteins 0.000 claims description 4
- 102000017910 Adrenergic receptor Human genes 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 8
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 4
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 4
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 2
- 229940122644 Chymotrypsin inhibitor Drugs 0.000 claims 2
- 101710137926 Chymotrypsin inhibitor Proteins 0.000 claims 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims 2
- 239000003541 chymotrypsin inhibitor Substances 0.000 claims 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 239000012747 synergistic agent Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 197
- 125000003396 thiol group Chemical group [H]S* 0.000 description 176
- -1 hydroxy, methoxy Chemical group 0.000 description 111
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 86
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 69
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 68
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 46
- 239000013067 intermediate product Substances 0.000 description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 235000019439 ethyl acetate Nutrition 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 27
- 238000005481 NMR spectroscopy Methods 0.000 description 26
- 239000007787 solid Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 17
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 17
- LRDIEHDJWYRVPT-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-1-sulfonic acid Chemical compound C1=CC(O)=C2C(N)=CC=C(S(O)(=O)=O)C2=C1 LRDIEHDJWYRVPT-UHFFFAOYSA-N 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 15
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 15
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 12
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 239000003862 glucocorticoid Substances 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 229940037128 systemic glucocorticoids Drugs 0.000 description 9
- 230000001919 adrenal effect Effects 0.000 description 8
- 239000005557 antagonist Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 8
- 229940044551 receptor antagonist Drugs 0.000 description 8
- 239000002464 receptor antagonist Substances 0.000 description 8
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 7
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 7
- 206010057190 Respiratory tract infections Diseases 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- UJJLJRQIPMGXEZ-SCSAIBSYSA-N tetrahydrofuran-2-carboxylic acid Chemical compound OC(=O)[C@H]1CCCO1 UJJLJRQIPMGXEZ-SCSAIBSYSA-N 0.000 description 7
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 6
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- LHMHCLYDBQOYTO-UHFFFAOYSA-N bromofluoromethane Chemical compound FCBr LHMHCLYDBQOYTO-UHFFFAOYSA-N 0.000 description 6
- 229910052731 fluorine Chemical group 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- UJJLJRQIPMGXEZ-BYPYZUCNSA-N (2s)-oxolane-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCO1 UJJLJRQIPMGXEZ-BYPYZUCNSA-N 0.000 description 5
- BOTREHHXSQGWTR-SCSAIBSYSA-N (3r)-oxolane-3-carboxylic acid Chemical compound OC(=O)[C@@H]1CCOC1 BOTREHHXSQGWTR-SCSAIBSYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000015696 Interleukins Human genes 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical group 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- JBCFJMYPJJWIRG-UHFFFAOYSA-N 1,3-oxazole-4-carboxylic acid Chemical compound OC(=O)C1=COC=N1 JBCFJMYPJJWIRG-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 4
- 201000010105 allergic rhinitis Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- WLNSKTSWPYTNLY-UHFFFAOYSA-N n-ethyl-n',n'-dimethylethane-1,2-diamine Chemical compound CCNCCN(C)C WLNSKTSWPYTNLY-UHFFFAOYSA-N 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 229960002052 salbutamol Drugs 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
- DHHFGQADZVYGIE-UHFFFAOYSA-N 9h-carbazole-1-carboxylic acid Chemical compound C12=CC=CC=C2NC2=C1C=CC=C2C(=O)O DHHFGQADZVYGIE-UHFFFAOYSA-N 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 3
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 229960002657 orciprenaline Drugs 0.000 description 3
- BOTREHHXSQGWTR-UHFFFAOYSA-N oxolane-3-carboxylic acid Chemical compound OC(=O)C1CCOC1 BOTREHHXSQGWTR-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 description 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- MMSNEKOTSJRTRI-LLVKDONJSA-N 1-[(2r)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea Chemical compound S1C(C#C[C@@H](C)N(O)C(N)=O)=CC=C1CC1=CC=C(F)C=C1 MMSNEKOTSJRTRI-LLVKDONJSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 2
- PMXLWQVHTIXUCE-UHFFFAOYSA-N 6-fluoropyridine-3-thiol Chemical compound FC1=CC=C(S)C=N1 PMXLWQVHTIXUCE-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 2
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000002691 Choroiditis Diseases 0.000 description 2
- 102100027995 Collagenase 3 Human genes 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000019872 Drug Eruptions Diseases 0.000 description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 208000032678 Fixed drug eruption Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 2
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 208000003971 Posterior uveitis Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- HODFCFXCOMKRCG-UHFFFAOYSA-N bitolterol mesylate Chemical compound CS([O-])(=O)=O.C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)C[NH2+]C(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 HODFCFXCOMKRCG-UHFFFAOYSA-N 0.000 description 2
- 229960000585 bitolterol mesylate Drugs 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 2
- 229960004590 diacerein Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 208000012587 fixed pigmented erythema Diseases 0.000 description 2
- 229960002848 formoterol Drugs 0.000 description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- DIDJZJDDXQPTLN-UHFFFAOYSA-N indazole-1-carboxylic acid Chemical compound C1=CC=C2N(C(=O)O)N=CC2=C1 DIDJZJDDXQPTLN-UHFFFAOYSA-N 0.000 description 2
- 229960001936 indinavir Drugs 0.000 description 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 229960001317 isoprenaline Drugs 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 229960005414 pirbuterol Drugs 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 229960004017 salmeterol Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229960003329 sulfinpyrazone Drugs 0.000 description 2
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960000195 terbutaline Drugs 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 208000000143 urethritis Diseases 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000011995 wilkinson's catalyst Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DVCFNCQPOANJGU-SCSAIBSYSA-N (2r)-oxolane-2-carbonyl chloride Chemical compound ClC(=O)[C@H]1CCCO1 DVCFNCQPOANJGU-SCSAIBSYSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- BOTREHHXSQGWTR-BYPYZUCNSA-N (3s)-oxolane-3-carboxylic acid Chemical compound OC(=O)[C@H]1CCOC1 BOTREHHXSQGWTR-BYPYZUCNSA-N 0.000 description 1
- JNUCBXOHYCABGJ-UHFFFAOYSA-N (4-fluorophenyl)phosphanium chloride Chemical compound [Cl-].FC1=CC=C([PH3+])C=C1 JNUCBXOHYCABGJ-UHFFFAOYSA-N 0.000 description 1
- QUPFKBITVLIQNA-KPKJPENVSA-N (5e)-2-sulfanylidene-5-[[5-[3-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-1,3-thiazolidin-4-one Chemical compound FC(F)(F)C1=CC=CC(C=2OC(\C=C\3C(NC(=S)S/3)=O)=CC=2)=C1 QUPFKBITVLIQNA-KPKJPENVSA-N 0.000 description 1
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- UMBFBAUZCQDTKX-VJLCOJPHSA-N (8s,9r,10s,11s,13s,14s,17r)-9-fluoro-11,17-dihydroxy-10,13-dimethyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-17-carboxylic acid Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(O)=O)[C@@H]4[C@@H]3CCC2=C1 UMBFBAUZCQDTKX-VJLCOJPHSA-N 0.000 description 1
- XNZSRYSTBKQWGZ-XLXYOEISSA-N (8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-17-carboxylic acid Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(O)=O)[C@@H]4[C@@H]3CCC2=C1 XNZSRYSTBKQWGZ-XLXYOEISSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- OLZHFFKRBCZHHT-SNVBAGLBSA-N 1-[(2r)-4-[5-(4-fluorophenoxy)furan-2-yl]but-3-yn-2-yl]-1-hydroxyurea Chemical compound O1C(C#C[C@@H](C)N(O)C(N)=O)=CC=C1OC1=CC=C(F)C=C1 OLZHFFKRBCZHHT-SNVBAGLBSA-N 0.000 description 1
- MWXPQCKCKPYBDR-UHFFFAOYSA-N 1-[4-[3-(4-fluorophenoxy)phenyl]but-3-yn-2-yl]-1-hydroxyurea Chemical compound NC(=O)N(O)C(C)C#CC1=CC=CC(OC=2C=CC(F)=CC=2)=C1 MWXPQCKCKPYBDR-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- ZJNLYGOUHDJHMG-UHFFFAOYSA-N 1-n,4-n-bis(5-methylhexan-2-yl)benzene-1,4-diamine Chemical compound CC(C)CCC(C)NC1=CC=C(NC(C)CCC(C)C)C=C1 ZJNLYGOUHDJHMG-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- YXEMPRTUAQVUOI-UHFFFAOYSA-N 2-chloroquinolin-3-ol Chemical compound C1=CC=C2N=C(Cl)C(O)=CC2=C1 YXEMPRTUAQVUOI-UHFFFAOYSA-N 0.000 description 1
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 1
- UCSPGOKFJCRSFN-UHFFFAOYSA-N 2-methoxyethylhydrazine;hydrochloride Chemical compound Cl.COCCNN UCSPGOKFJCRSFN-UHFFFAOYSA-N 0.000 description 1
- XTDKZSUYCXHXJM-UHFFFAOYSA-N 2-methoxyoxane Chemical compound COC1CCCCO1 XTDKZSUYCXHXJM-UHFFFAOYSA-N 0.000 description 1
- GINJNNGWMNSBIG-UHFFFAOYSA-N 2-n-methylpropane-1,2-diamine Chemical compound CNC(C)CN GINJNNGWMNSBIG-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- AXUZQJFHDNNPFG-LHAVAQOQSA-N 3-[(r)-[3-[(e)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-[3-(dimethylamino)-3-oxopropyl]sulfanylmethyl]sulfanylpropanoic acid Chemical compound CN(C)C(=O)CCS[C@H](SCCC(O)=O)C1=CC=CC(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)=C1 AXUZQJFHDNNPFG-LHAVAQOQSA-N 0.000 description 1
- IHCCAYCGZOLTEU-UHFFFAOYSA-M 3-furoate Chemical compound [O-]C(=O)C=1C=COC=1 IHCCAYCGZOLTEU-UHFFFAOYSA-M 0.000 description 1
- BIAVGWDGIJKWRM-FQEVSTJZSA-N 3-hydroxy-2-phenyl-n-[(1s)-1-phenylpropyl]quinoline-4-carboxamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(O)C=1C1=CC=CC=C1 BIAVGWDGIJKWRM-FQEVSTJZSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- MBLJFKQACMILLC-UHFFFAOYSA-N 4-[[3-[[4-[2-(4-hydroxyphenyl)propan-2-yl]phenoxy]methyl]phenyl]methoxy]benzenecarboximidamide Chemical compound C=1C=C(OCC=2C=C(COC=3C=CC(=CC=3)C(N)=N)C=CC=2)C=CC=1C(C)(C)C1=CC=C(O)C=C1 MBLJFKQACMILLC-UHFFFAOYSA-N 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 description 1
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 102100021253 Antileukoproteinase Human genes 0.000 description 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
- AAXBPADOCIHMNS-UHFFFAOYSA-N C1=CC=C2C(=C1)C=NN2COCC(=O)O Chemical compound C1=CC=C2C(=C1)C=NN2COCC(=O)O AAXBPADOCIHMNS-UHFFFAOYSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 108010017319 CCR1 Receptors Proteins 0.000 description 1
- 102000004500 CCR1 Receptors Human genes 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- 229940124003 CRTH2 antagonist Drugs 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000006081 Cryptococcal meningitis Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 1
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 102100040278 E3 ubiquitin-protein ligase RNF19A Human genes 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010065563 Eosinophilic bronchitis Diseases 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 208000027445 Farmer Lung Diseases 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical class [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940123538 Glucose-6 phosphate dehydrogenase inhibitor Drugs 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 1
- 101000615334 Homo sapiens Antileukoproteinase Proteins 0.000 description 1
- 101000798902 Homo sapiens Atypical chemokine receptor 4 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 description 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 1
- 101000926939 Homo sapiens Glucocorticoid receptor Proteins 0.000 description 1
- 101001071608 Homo sapiens Glutathione reductase, mitochondrial Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 101150069380 JAK3 gene Proteins 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700041567 MDR Genes Proteins 0.000 description 1
- 101150014058 MMP1 gene Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 206010027209 Meningitis cryptococcal Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 229940099547 Neuronal nitric oxide synthase inhibitor Drugs 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- 108030001564 Neutrophil collagenases Proteins 0.000 description 1
- 102000056189 Neutrophil collagenases Human genes 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 241001420836 Ophthalmitis Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 1
- 101710189965 P2X purinoceptor 7 Proteins 0.000 description 1
- 239000012826 P38 inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000004362 Penile Induration Diseases 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000020758 Peyronie disease Diseases 0.000 description 1
- KJFMBFZCATUALV-UHFFFAOYSA-N Phenolphthalein Natural products C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 208000011191 Pulmonary vascular disease Diseases 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 101100545004 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YSP2 gene Proteins 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 229940121742 Serine/threonine kinase inhibitor Drugs 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 101000879712 Streptomyces lividans Protease inhibitor Proteins 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 206010057970 Toxic skin eruption Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 230000010632 Transcription Factor Activity Effects 0.000 description 1
- 229940123468 Transferase inhibitor Drugs 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229940122598 Tryptase inhibitor Drugs 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229940116731 Uricosuric agent Drugs 0.000 description 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047112 Vasculitides Diseases 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000035222 X-linked skeletal dysplasia-intellectual disability syndrome Diseases 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- FGGYJWZYDAROFF-UHFFFAOYSA-N ablukast Chemical compound CCCC1=C(O)C(C(C)=O)=CC=C1OCCCCCOC(C(=C1)C(C)=O)=CC2=C1CCC(C(O)=O)O2 FGGYJWZYDAROFF-UHFFFAOYSA-N 0.000 description 1
- 229950006882 ablukast Drugs 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 108010003059 aggrecanase Proteins 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005599 alkyl carboxylate group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000000584 angiotensin II type 2 receptor blocker Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002255 antigout agent Substances 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 1
- 229960004168 balsalazide Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Chemical class [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 229950002826 canertinib Drugs 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- USJRLGNYCQWLPF-UHFFFAOYSA-N chlorophosphane Chemical compound ClP USJRLGNYCQWLPF-UHFFFAOYSA-N 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 108700004333 collagenase 1 Proteins 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- 229950011148 cyclopropane Drugs 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960002311 dithranol Drugs 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- SBVYURPQULDJTI-UHFFFAOYSA-N ethyl n-[amino-[4-[[3-[[4-[2-(4-hydroxyphenyl)propan-2-yl]phenoxy]methyl]phenyl]methoxy]phenyl]methylidene]carbamate Chemical compound C1=CC(C(=N)NC(=O)OCC)=CC=C1OCC1=CC=CC(COC=2C=CC(=CC=2)C(C)(C)C=2C=CC(O)=CC=2)=C1 SBVYURPQULDJTI-UHFFFAOYSA-N 0.000 description 1
- LENNRXOJHWNHSD-UHFFFAOYSA-N ethylnorepinephrine Chemical compound CCC(N)C(O)C1=CC=C(O)C(O)=C1 LENNRXOJHWNHSD-UHFFFAOYSA-N 0.000 description 1
- 229960002267 ethylnorepinephrine Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 208000022195 farmer lung disease Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950002170 fenleuton Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940015042 glycopyrrolate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 239000002474 gonadorelin antagonist Substances 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 229960004078 indacaterol Drugs 0.000 description 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- OTZRAYGBFWZKMX-JUDRUQEKSA-N leukotriene E4 Chemical compound CCCCCC=CCC=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O OTZRAYGBFWZKMX-JUDRUQEKSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960001120 levocabastine Drugs 0.000 description 1
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 229940126170 metalloproteinase inhibitor Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229960001952 metrifonate Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 1
- VLUXBNSRYHXDBV-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-4,5-dihydro-1,3-thiazol-2-amine Chemical compound CC1=CC=CC(C)=C1NC1=NCCS1 VLUXBNSRYHXDBV-UHFFFAOYSA-N 0.000 description 1
- RVXKHAITGKBBAC-SFHVURJKSA-N n-[(1s)-2-cyclohexyl-1-pyridin-2-ylethyl]-5-methyl-1,3-benzoxazol-2-amine Chemical compound C([C@H](NC=1OC2=CC=C(C=C2N=1)C)C=1N=CC=CC=1)C1CCCCC1 RVXKHAITGKBBAC-SFHVURJKSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- AZKDTTQQTKDXLH-UHFFFAOYSA-N napthalene-2-carbonitrile Natural products C1=CC=CC2=CC(C#N)=CC=C21 AZKDTTQQTKDXLH-UHFFFAOYSA-N 0.000 description 1
- 229960002259 nedocromil sodium Drugs 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- CMUOJBJRZUHRMU-UHFFFAOYSA-N nitrourea Chemical compound NC(=O)N[N+]([O-])=O CMUOJBJRZUHRMU-UHFFFAOYSA-N 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 102000027419 nuclear receptor subfamilies Human genes 0.000 description 1
- 108091008607 nuclear receptor subfamilies Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229950010666 ontazolast Drugs 0.000 description 1
- 208000005963 oophoritis Diseases 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001609 oxitropium bromide Drugs 0.000 description 1
- LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
- DVCFNCQPOANJGU-UHFFFAOYSA-N oxolane-2-carbonyl chloride Chemical compound ClC(=O)C1CCCO1 DVCFNCQPOANJGU-UHFFFAOYSA-N 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 208000010403 panophthalmitis Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960002934 propentofylline Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 229960000786 propylhexedrine Drugs 0.000 description 1
- JCRIVQIOJSSCQD-UHFFFAOYSA-N propylhexedrine Chemical compound CNC(C)CC1CCCCC1 JCRIVQIOJSSCQD-UHFFFAOYSA-N 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical compound O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- WDXARTMCIRVMAE-UHFFFAOYSA-N quinoline-2-carbonitrile Chemical class C1=CC=CC2=NC(C#N)=CC=C21 WDXARTMCIRVMAE-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- GZKMGAXTHYGXEO-UHFFFAOYSA-M ruthenium(1+);triphenylphosphane;chloride Chemical compound [Ru]Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 GZKMGAXTHYGXEO-UHFFFAOYSA-M 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
- 229960002078 sevoflurane Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000025869 skeletal dysplasia-intellectual disability syndrome Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- YPURUCMVRRNPHJ-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C12=CC=C(OCC=3N=C4C=CC=CC4=CC=3)C=C2C(SC(C)(C)C)=C(CC(C)(C)C([O-])=O)N1CC1=CC=C(Cl)C=C1 YPURUCMVRRNPHJ-UHFFFAOYSA-M 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 125000004964 sulfoalkyl group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229950011332 talnetant Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940000238 tasmar Drugs 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 description 1
- 229950009638 tepoxalin Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UJJLJRQIPMGXEZ-UHFFFAOYSA-N tetrahydro-2-furoic acid Chemical compound OC(=O)C1CCCO1 UJJLJRQIPMGXEZ-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- PHCBRBWANGJMHS-UHFFFAOYSA-J tetrasodium;disulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O PHCBRBWANGJMHS-UHFFFAOYSA-J 0.000 description 1
- 229960000337 tetryzoline Drugs 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229960001262 tramazoline Drugs 0.000 description 1
- QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002750 tryptase inhibitor Substances 0.000 description 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000003383 uricosuric agent Substances 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229950003905 verlukast Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000007966 viscous suspension Substances 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- UTODFRQBVUVYOB-UHFFFAOYSA-P wilkinson's catalyst Chemical compound [Cl-].C1=CC=CC=C1P(C=1C=CC=CC=1)(C=1C=CC=CC=1)[Rh+](P(C=1C=CC=CC=1)(C=1C=CC=CC=1)C=1C=CC=CC=1)P(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 UTODFRQBVUVYOB-UHFFFAOYSA-P 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0047—Nitrogen only at position 2(3)
Description
本發明係關於具備醣皮質類固醇受體(glucocorticosteroid receptor)協同劑活性之化合物,其醫藥上組成物及其用途,尤其用於治療發炎與過敏性病症。
醣皮質類固醇(GCs)具備抗發炎特性係已習知,並廣泛用於治療發炎性關節炎(例如類風濕性關節炎、僵直性脊椎炎及乾癬性關節病變)、其他類風濕性病症如例如全身性紅斑性狼瘡、硬皮症、血管炎包括顳動脈炎與多發性結節性動脈炎、發炎性腸道疾病如克隆氏症(Crohns disease)與潰瘍性大腸炎、肺部疾病如氣喘與慢性阻塞性氣道疾病,以及許多其他症狀如風濕性多發性肌痛症等病症。GCs亦因其免疫抑制性而相當廣泛地用於預防與治療移植排斥作用。最近GCs因其抗腫瘤功效而用於多種惡性腫瘤。
GCs係經由特定之腎上腺醣皮質激素受體GR)作用,該受體為細胞核受體次家族之成員。配體結合作用可促進受體二聚合化(dimerisation)、DNA結合及轉錄活化作用。GC之活體外作用機制已經明確,對於調節下視丘-腦下垂體-腎上腺軸、糖質新生作用,以及抗發炎基因如分裂素活化蛋白激酶去磷酸酶-1(MKP-1),及分泌性白血球蛋白酶抑制物(SLPI),之體內轉錄作用相當重要。配體結合型受體亦可以二聚合化方式抑制基因轉錄作用,係干擾轉錄因子活性,如AP-1與NFkB,其於發炎反應中相當重要。
受體結合後,GR由細胞質轉位至細胞核,並結合至標的基因調節區上之腎上腺醣皮質激素反應區。經活化GR隨即招募共同活化因子,包括腎上腺醣皮質激素受體作用蛋白1(GRIP-1)與類固醇受體共同活化因子1(SRC1)。這些輔助蛋白結合至受體並聯結GR進行標的基因之轉錄作用。
腎上腺醣皮質激素之轉錄作用除了藉由經活化GR直接結合至標的DNA、同質二聚合化與召集共同活化因子(即“轉錄活化(transactivation)作用”)等作用外,亦包括以GR干擾其他轉錄因子功能,包括AP-1與NFκB,係與其他轉錄因子錯合,並防止其結合至標的基因,進而抑制通常會被AP-1或NFκB加強調節之基因表現(即“轉錄抑制作用(transrepession)”)。此兩種受體活性作用模式不相關,且轉錄活化作用不存在時,對於NFκB活性之負面作用仍維持。似乎轉錄抑制作用與GR治療所希望之抗發炎反應活性有較大關係。有趣的是,抑制AP-1或NFκB(0.04 nM)之IC50
低於活化標的基因之EC50
(5nM),而治療發炎疾病患者常需要高劑量GCs。一種解釋認為,發炎部位表現之細胞生長激素可誘發相關的腎上腺醣皮質激素拮抗反應,例如活化AP-1或NFκB。這相當重要,因為許多促發炎反應(pro-inflammatory)細胞生長激素係因活化NFκB而傳遞訊息,而GCs的其中一種主要抗發炎作用被認為是藉由對抗NFκB之作用而傳達。
已公開之日本專利申請號6006749描述了使用pregnenopyrazoles作為抗發炎劑。
吾人之審查中國際專利申請案號PCT/GB2008/050890,係相關於下式化合物
其中X1
、X2
、X3
、X4
與X5
每一者皆獨立地代表CH或氮原子,其中X1
、X2
、X3
、X4
與X5
中之不大於二者可同時為氮原子;n與p每一者皆獨立地代表0或1;R1
代表鹵素原子或甲基或甲氧基;R2
代表鹵素原子、-C(O)OCH3
、-C(O)-S-CH2
CN、-C(O)-S-CH3
、-C(O)-雜環基、-SO2
CH3
、C2
-C6
烯基,或甲基,其任擇地經鹵素、羥基、甲氧基、-OCH2
CH=CH2
或-NR7
R8
取代;R3a
代表氫原子或甲基,且R3b
代表氫或氟原子;R4
代表-C(O)-S-C(O)N(CH3
)2
、-C(O)CH2
Cl、-C(O)-Y-CH(R11
)-R9
或-C(O)-CH(R11
)-Y-R9
;R5
代表羥基、-OCH2
SCH3
、-O-C(O)-R10
、-O-C(O)-NH-R10
、-O-C(O-O-R10
或-O-C(O)-S-R10
;R6
代表氫或鹵素原子或甲基,且當R5
非羥基時,R6
可額外地代表一羥基;R7
與R8
每一者皆獨立地代表氫原子,或C1
-C3
烷基或C1
-C3
羥基烷基,或R7
與R8
可與其上所連結的氮原子共同形成一3-至8-元飽和或部分飽和雜環,其任擇地含有另一環上雜基團,選自於氮、S(O)m
與氧,且該雜環可選擇性地經至少一取代基取代,該取代基選自於羥基、C1
-C3
烷基與C1
-C3
羥基烷基;m係0、1或2;Y代表氧或硫原子或基團>NH;R9
代表氫、鹵素、氰、-S-CN、-C(O)N(R12
)2
、C1
-C6
烷氧基羰基、C1
-C6
烷基羰基(選擇性地經-OC(O)CH3
取代)、C1
-C6
烷基羰基氧基、C1
-C6
烷氧基、C1
-C6
烷基硫基、-C(O)-S-C1
-C6
烷基、-C(=CH2
)-O-CH2
OCH3
、C1
-C6
烷基、C2
-C6
烯基、C2
-C6
炔基或C3
-C7
環烷基,後四基團可任擇地經一或多個取代基取代,該取代基獨立地選自於鹵素、羥基、氰基、羥基甲基、C1
-C4
烷氧基以及C1
-C4
烷基羰基氧基;R10
代表C1
-C6
烷基(任擇地經鹵素、C1
-C4
烷氧基、C1
-C4
烷基羰基氧基或C3
-C7
環烷基取代),或3-至10-元飽和或未飽和碳環或雜環系統,其中該環系統可任擇地經至少一取代基取代,該取代基選自於鹵素、羧基、羥基、氧基、硝基、氰基、巰基、C1
-C6
烷基、C2
-C6
烯基、C1
-C6
鹵化烷基、C1
-C6
羥基烷基、C1
-C6
烷氧基、C1
-C6
鹵化烷氧基、C1
-C6
烷基硫基、C1
-C6
烷基亞磺醯基、C1
-C6
烷基磺醯基、C1
-C6
烷基羰基、C1
-C6
烷基羰基氧基、C1
-C6
烷氧基羰基、胺基(-NH2
)、醯胺基(-CONH2
)、(單)C1
-C6
烷基胺基、(二)C1
-C6
烷基胺基,以及苯基;R11
代表氫原子或甲基;以及每一R12
皆獨立地代表氫原子或甲基;其中當R4
代表-C(O)CH2
OH、-C(O)CH2
OC(O)C2
H5
或-C(O)CH2
Cl時,X1
、X2
、X3
、X4
與X5
之每一者皆代表CH,以及當R5
代表-O-C(O)-R10
,其中R10
代表C1
-C6
烷基時,R1
與R2
至少有一者存在;或其醫藥上可接受鹽類。
本發明提供落於式(I)化合物範疇中之化合物,但其並未特定揭露於上述吾人之審查中國際專利案號PCT/GB2008/050890中
因此,本發明提供如前述所定義之式(I)化合物,係選自於由:(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環丙烷羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2R)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2R)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-1-{[(2-羥基乙基)硫烷基]羰基}-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2R)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基四氫呋喃63-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(R)/(S)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(S)/(R)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(R)/(S)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(S)/(R)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2S)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aR,10bS,11S,12aS)-7-(4-氟苯基)-11-羥基-1-{[(2-羥基乙基)硫烷基]羰基}-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(S)/(R)四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[氰甲基氧基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[氰甲基氧基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環丙烷羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基呋喃-2-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基呋喃-2-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環丙烷羧酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯,以及(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯,或其醫藥上可接受鹽類組成之族群。
應注意到上述之每一化合物皆代表本發明之特定與獨立觀點。
上述及本發明之式(I)化合物可製成醫藥上可接受之鹽類,例如酸加成鹽類,如鹽酸鹽、溴酸鹽、三氟醋酸鹽、硫酸鹽、磷酸鹽、醋酸鹽、富馬鹽、蘋果酸鹽、酒石酸鹽、乳酸鹽、檸檬酸鹽、丙酮酸鹽、琥珀酸鹽、草酸鹽、甲基磺酸鹽或對甲苯磺酸鹽。
應瞭解到本發明化合物及其醫藥上可接受鹽類可以媒合物形式存在,例如水合物,及非媒合物形式,且本發明包含所有此類媒合物形式。互變體及其混合物亦形成本發明之一觀點。
本發明化合物及其醫藥上可接受鹽類具備如藥物之活性,特別是可作為腎上腺醣皮質激素受體活性之調節劑,因此可用於下列之治療:
1. 呼吸道:氣管阻塞性疾病包括:氣喘,包括支氣管、過敏、內在、外在、運動誘發性、藥物誘發性(包括阿斯匹靈與NSAID誘發性)與粉塵誘發性氣喘,週期性與持續性之嚴重性,以及呼吸道過度反應之其他原因;慢性阻塞性肺病(COPD);支氣管炎,包括感染性與嗜伊紅性支氣管炎;肺氣腫(emphysema);支氣管擴張(bronchiectasis);囊胞性纖維症(cystic fibrosis);肉狀瘤病(sarcoidosis);農夫肺(farmer’s lung)與相關疾病;過敏性肺炎;肺纖維化,包括隱源性纖維性肺泡炎(cryptogenic fibrosing alveolitis)、特發性肺纖維化(idiopathic interstitial pneumonias)、纖維化併發抗腫瘤治療及慢性感染,包括結核病與黴菌症(aspergillosis)及其他真菌感染;肺移植併發症;肺動脈血管與血栓失調,與肺動脈高血壓;抗組織活性,包括治療慢性咳嗽而產生的氣管發炎性與分泌性症狀,以及幻想性咳嗽(iatrogenic cough);急性與慢性鼻炎(rhinitis),包括藥物性鼻炎(rhinitis medicamentosa)與血管運動性鼻炎(vasomotor rhinitis);常年性與季節變應性鼻炎,包括神經性鼻炎(rhinitis nervosa)(枯草熱);鼻息肉症(nasal polyposis);急性病毒感染,包括常見感冒,以及呼吸道融合病毒、流感病毒、冠狀病毒(包括SARS)與腺病毒之感染;
2. 皮膚:牛皮癬(psoriasis)、異位性皮炎(atopic dermatitis)、接觸性皮炎或其他濕疹性皮膚病(eczematous dermatoses)與遲緩型過敏反應;光接觸性皮炎(phyto- and photodermatitis);脂溢性皮膚炎(seborrhoeic Dermatitis)、皰疹狀皮膚炎(dermatitis herpetiformis)、扁平苔癬(lichen planus)、萎縮硬化性苔癬(lichen sclerosus et atrophica)、壞疽性膿皮病(pyoderma gangrenosum)、皮膚肉樣瘤(skin sarcoid)、盤狀紅斑狼瘡(discoid lupus erythematosus)、天皰瘡(pemphigus)、天皰瘡(pemphigoid)、表皮分解性水皰症(epidermolysis bullosa)、蕁麻疹(urticaria)、血管性水腫(angioedema)、血管炎(vasculitides)、中毒性紅腫(toxic erythemas)、皮膚嗜酸粒細胞增多症(cutaneous eosinophilias)、班禿(alopecia areata)、雄性禿(male-pattern baldness)、史維特症候群(Sweet’s syndrome)、韋伯-克里斯琴症候群(Weber-Christian syndrome)、多形性紅斑(erythema multiforme);蜂窩性組織炎(cellulites),包括感染性與非感染性;脂膜炎(panniculitis);皮膚淋巴瘤(cutaneous lymphomas)、非黑色素細胞瘤皮膚癌與其他分化不良之病變;藥物誘發性失調,包括固定型藥疹(fixed drug eruptions);
3. 眼睛:眼瞼炎(blepharitis);結膜炎(conjunctivitis),包括常年性與春季型過敏性結膜炎(perennial and vernal allergic conjunctivitis);虹膜炎(iritis);前與後葡萄膜炎(anterior and posterior uveitis);脈絡膜炎(choroiditis);自體免疫性、退化性或發炎性失調以影響視網膜;眼球炎(ophthalmitis),包括交感性眼炎(sympathetic ophthalmitis);結節病(sarcoidosis);感染,包括病毒性、真菌性與細菌性;
4. 泌尿生殖器:腎炎(nephritis),包括間隙型與腎絲球腎炎型(interstitial and glomerulonephritis);腎病症候群;膀胱炎(cystitis),包括急性與慢性(間隙型)膀胱炎與胡樂氏潰瘍(Hunner’s ulcer);急性與慢性尿道炎(urethritis)、前列腺炎(prostatitis)、副睪丸炎(epididymitis)、卵巢炎(oophoritis)與輸卵管炎(salpingitis);陰戶陰道炎(vulvo-vaginitis);佩洛尼氏病(Peyronie’s disease);勃起功能障礙((erectile dysfunction)(包括雄性與雌性);
5. 移植排斥:以下之急性與慢性情況,舉例而言,腎臟、心臟、肝臟、肺臟、骨髓、皮膚或眼角膜移植,或輸血;或宿主慢性排斥;
6. 其他自體免疫與過敏性失調,包括類風濕性關節炎、激躁性結腸症(irritable bowel syndrome)、全身性紅斑性狼瘡(systemic lupus erythematosus)、多發性硬化症(multiple sclerosis)、橋本氏甲狀腺炎(Hashimoto’s thyroiditis)、葛瑞夫茲氏病(Graves’ disease)、愛迪生氏症(Addison’s disease)、糖尿病、自發性血小板缺乏紫斑症(idiopathic thrombocytopenic purpura)、嗜酸性筋膜炎(eosinophilic fasciitis)、高IgE症候群、抗磷脂質症與薩沙里症候群(Sazary syndrome);
7. 腫瘤學:常見癌症之治療,包括攝護腺、乳房、肺臟、卵巢、胰臟、腸與結腸、胃臟、皮膚與腦部腫瘤及影響骨髓(包括,白血病)及淋巴增生系統,例如霍奇金氏與非霍奇金氏淋巴癌(Hodgkin’s and non-Hodgkin’s lymphoma)之惡性疾病;包括轉移性疾病與腫瘤再發之預防與治療,及副腫瘤併發症;以及
8. 感染性病症:病毒性疾病,例如生殖器官疣(genital warts)、扁平疣(common warts)、足蹠疣(plantar warts)、B型肝炎、C型肝炎、單純疱疹病毒(herpes simplex virus)、觸染性軟疣(molluscum contagiosum)、天花(variola)、人類免疫缺陷病毒(HIV)、人類乳頭狀瘤病毒(HPV)、巨細胞病毒(CMV)、水痘帶狀皰疹病毒(VZV)、鼻病毒(rhinovirus)、腺病毒、冠狀病毒、流行性感冒病毒、副流行性感冒病毒(para-influenza);細菌性疾病,例如肺結核與鳥分枝桿菌(mycobacterium avium)、麻瘋病(leprosy);其他感染性疾病,例如真菌類疾病、衣原體(chlamydia)、念珠菌(candida)、曲黴屬真菌(aspergillus)、隱球菌腦膜炎(cryptococcal meningitis)、卡式肺囊蟲(pneumocystis carnii)、隱孢子蟲病(cryptosporidiosis)、組織漿菌症(histoplasmosis)、弓蟲症(toxoplasmosis)、錐蟲感染(trypanosome infection)與利什曼原蟲病(leishmaniasis)。
因此,本發明提供如前述所定義之式(I)化合物,係選自於由:(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-惡唑-4-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2R)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2R)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-1-{[(2-羥基乙基)硫烷基]羰基}-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2R)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(R)/(S)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(S)/(R)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(R)/(S)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(S)/(R)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2S)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aR,10bS,11S,12aS)-7-(4-氟苯基)-11-羥基-1-{[(2-羥基乙基)硫烷基]羰基}-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(S)/(R)四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[氰甲基氧基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[氰甲基氧基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基呋喃-2-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基呋喃-2-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯,以及(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯,或其醫藥上可接受鹽類組成之族群,用於醫療用途。
在另一觀點中,本發明係提供式(I)化合物之用途,該化合物如前述定義並選自於:(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2R)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2R)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-1-{[(2-羥基乙基)硫烷基]羰基}-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2R)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(R)/(S)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(S)/(R)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(R)/(S)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(S)/(R)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2S)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aR,10bS,11S,12aS)-7-(4-氟苯基)-11-羥基-1-{[(2-羥基乙基)硫烷基]羰基}-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(S)/(R)四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[氰甲基氧基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[氰甲基氧基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基呋喃-2-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基呋喃-2-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯,以及(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯,或其醫藥上可接受鹽類組成之族群,用於製造治療用途之藥物。
於本說明書全文之中,術語“治療”亦包括“預防”,除非另有說明。“治療性”與“治療上”等詞可據此以為解釋。
預防係預期特別與先前已發作過,或被認為具有較高風險罹患該疾病或症狀之個體之治療有關。有風險發展出特定疾病或症狀之個體,一般包括具有該疾病或症狀之家族史者,或是經過基因測試或篩選,而被認定特別可能發展出該疾病或症狀者。
尤其是,本發明化合物(包括醫藥上可接受鹽類)可用於治療氣喘{例如支氣管、過敏、內在、外在或粉塵性氣喘,特別是慢性或積習性氣喘(例如晚發性氣喘或呼吸道過度反應症)}、慢性阻塞性肺病(COPD)或過敏性鼻炎。
本發明亦提供一種方法,以治療或降低罹患阻塞性呼吸道疾病或症狀(例如,氣喘或COPD)之風險,包含投予有需要之病患治療有效劑量之式(I)化合物,如前述所定義,係選自於由:(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡唑-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2R)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2R)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-1-{[(2-羥基乙基)硫烷基]羰基}-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2R)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(R)/(S)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(S)/(R)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(R)/(S)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(S)/(R)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2S)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aR,10bS,11S,12aS)-7-(4-氟苯基)-11-羥基-1-{[(2-羥基乙基)硫烷基]羰基}-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(S)/(R)四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[氰甲基氧基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[氰甲基氧基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基呋喃-2-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基呋喃-2-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯,以及(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯,或其醫藥上可接受鹽類組成之族群。
就上述之治療用途而言,所投予之劑量會隨著所使用之化合物、投藥模式、希望之治療,以及該病症而不同。例如,若為吸入式,本發明化合物之每日劑量範圍為0.05微克每公斤體重(μg/kg)至100微克每公斤體重(μg/kg)。此外,若該化合物為口服投藥,則本發明化合物之每日劑量範圍為0.01微克每公斤體重(μg/kg)至100毫克每公斤體重(mg/kg)。
本發明化合物及其醫藥上可接受鹽類可單獨使用,但一般而言係以醫藥組成物方式投藥,其中本化合物/鹽類(活性成分)係結合醫藥上可接受之佐劑、稀釋劑或載體。常見之適用醫藥配方之選擇與製備方法係揭示於例如,“Pharmaceuticals-The Science of Dosage Form Designs”,M. E. Aulton,Churchill Livingstone,1988。
依據投藥方式,本發明醫藥組成物較佳之情況為包含由0.05至99%W(重量百分比),更佳之情況為由0.05至80%w,尤佳之情況為由0.10至70%w,最佳之情況為由0.10至50%w之活性成分,其中所有的重量百分比係依據總組成物之重量為基準。
本發明亦提供醫藥組成物,包含如前述所定義式(I)化合物,係選自於由:(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2R)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2R)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-1-{[(2-羥基乙基)硫烷基]羰基}-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2R)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(R)/(S)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(S)/(R)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(R)/(S)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(S)/(R)四氫呋喃-3-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(2S)-四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aR,10bS,11S,12aS)-7-(4-氟苯基)-11-羥基-1-{[(2-羥基乙基)硫烷基]羰基}-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基(S)/(R)四氫呋喃-2-羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[氰甲基氧基]羰基}-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,3aS,3bS,10aS,10bR,11S,12aS)-1-{[氰甲基氧基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基呋喃-2-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基呋喃-2-羧酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-1-{[(氟甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-5,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基環戊烷羧酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基丙酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氟甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯、(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(4-氟苯基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基1,3-噁唑-4-羧酸酯,以及(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-1-{[(氰甲基)硫烷基]羰基}-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-基甲氧基醋酸酯,或其醫藥上可接受鹽類組成之族群,並結合醫藥上可接受之佐劑、稀釋劑或載體。
本發明更提供一種製備本發明醫藥組成物之方法,包含將本發明化合物或其醫藥上可接受鹽類與醫藥上可接受之佐劑、稀釋劑或載體混合。
醫藥組成物可局部投藥(例如,至皮膚、肺臟與/或呼吸道),以如乳霜、溶液、懸浮液、七氟烷烴(HFA)氣膠與乾燥粉末配方,如配製於名為吸入器裝置中之配方等形式;或全身性投藥,例如口服藥錠、膠囊、糖漿、粉末或細粒形式;或非經腸胃投藥,以用於注射之無菌溶液、懸浮液或乳化物形式(包括靜脈注射、皮下注射、肌肉注射、血管內注射或輸液);或於直腸投予栓劑形式。
本發明化合物及其醫藥上可接受鹽類之乾粉配方與加壓式HFA噴霧,可以口或鼻吸入方式頭藥。在吸入投藥方面,化合物/鹽類較佳經微細分散化處理。經微細分散之化合物/鹽類較佳具有質量中間數直徑小於10微米(μm),且可經分散劑協助懸浮於推進劑混合物中,如C8
-C20
脂肪酸或其鹽類(例如,油酸)、膽鹽、磷脂質、烷基醣類、過氟化或聚乙氧基化界面活性劑,或其他醫藥上可接受之分散劑。
本發明化合物及其醫藥上可接受鹽類亦可以乾粉吸入劑方式給藥。吸入劑可為單劑量或多劑量吸入劑,且可為呼吸促動型乾粉吸入劑。
一種可能性為將微細分散之化合物/鹽類與載體物質,例如單、雙或多醣、醣醇或另一多元醇(polyol)混合。適用之載體為糖類,例如乳糖、葡萄糖、棉子糖(raffinose)、松三糖(melezitose)、乳糖醇(lactitol)、麥芽糖醇(maltitol)、海藻糖(trehalose)、蔗糖、甘露醇(mannitol);以及澱粉。或者,該經微細分散之化合物/鹽類可包覆上另一物質。粉末混合物亦可分裝於硬膠囊中,每一者含有所希望劑量之活性成分。
另一可能性為將微細分散之化合物/鹽類加工入球體內,其會於吸入過程中破裂。此球體化粉末可填入多劑型吸入劑儲藥槽中,如習知之,其中投劑單元可定量所希望之藥量,之後被病患吸入。藉由此系統,活性成分無論有無結合載體物質,均可送入病患體內。
在口服投藥方面,本發明化合物(或其醫藥上可接受鹽類)可與佐劑或載體混合,例如乳糖、蔗糖、山梨醇(sorbitol)、甘露醇;澱粉,例如馬鈴薯澱粉、玉米澱粉或澱粉果膠(amylopectin);纖維素衍生物;結合劑,例如明膠或聚乙烯吡咯烷酮(polyvinylpyrrolidone);及/或潤滑劑,例如硬脂酸鎂、硬脂酸鈣、聚乙二醇、蠟、石蠟及其類似物,並隨即壓製成藥錠。若需要經包覆藥錠,如前述製備之核心可經濃縮糖類溶液塗覆,其可包含如阿拉伯膠、明膠、滑石與二氧化鈦。或者,該藥錠可塗覆一溶於易揮發有機溶劑之適用聚合物。
在製備軟膠囊方面,本發明化合物(或其醫藥上可接受鹽類)可與如植物油或聚乙二醇混合。硬膠囊可內含該化合物/鹽類細粒,使用前述藥錠之賦形劑。本發明化合物之水性或半固態配方亦可填充至硬膠囊中。
口服用之液體製劑可為糖漿或懸浮液形式,例如含有本發明化合物之溶液、糖類調和物,及乙醇、水、甘油與聚乙二醇之混合物。任擇地,此類液體製劑可包含增色劑、香味劑、糖精(saccharine)及/或作為增稠劑之羧甲基纖維素,或其他熟習此技術領域者所知之賦形劑。
本發明化合物及其醫藥上可接受鹽類亦可組合其他化合物投藥,以用於治療上述病症之用途。
本發明因此更相關於一種組合式治療,其中本發明化合物或其醫藥上可接受鹽類,或含有本發明化合物或其醫藥上可接受鹽類之醫藥組成物或配方,係同時或依序或與另一藥劑或試劑組合投藥,以治療一或更多所列之病症。
尤其是,在治療發炎性疾病方面,例如(但不侷限於此)類風濕性關節炎、骨關節炎(osteoarthritis)、氣喘、過敏性鼻炎、慢性阻塞性肺病(COPD)、牛皮癬(psoriasis)與發炎性腸症,本發明化合物及其醫藥上可接受鹽類可結合下列藥劑:非固醇類抗發炎用藥(以下稱為NSAIDs),包括非選擇性環氧化酶COX-1/COX-2抑制劑,可局部性或全身性給藥(例如匹羅斯康(piroxicam)、雙氯芬(diclofenac)、丙酸,例如那波松(naproxen)、福畢普芬(flurbiprofen)、芬諾普芬(fenoprofen)、酮普芬(ketoprofen)與衣布普芬(ibuprofen)、滅酸鹽(fenamates),如甲滅酸(mefenamic acid)、吲哚美辛(indomethacin)、蘇林達(sulindac)、吖丙嗪酮(azapropazone)、吡唑啉酮,如苯基保太松、水楊酸鹽,例如阿司匹靈);選擇性COX-2抑制劑(例如美羅司康(meloxicam)、思來考昔(celecoxib)、羅芙考昔(rofecoxib)、凡迪考昔(valdecoxib)、錄麻考昔(lumarocoxib)、愛瑞考昔(arecoxib)與依托考昔(etoricoxib));環氧化酶抑制一氧化氮提供者(CINODs);腎上腺醣皮質激素(無論局部、口服、肌肉注射、靜脈注射或關節內注射途徑給藥);甲胺蝶呤(methotrexate);來氟米特(leflunomide);羥基氯喹啉;d-盤尼西林胺;金諾芬(auranofin)或其他非口服或口服金製劑;止痛劑;雙醋瑞因(diacerein);關節內治療,例如玻尿酸衍生物;以及營養補充物,例如葡萄糖胺。
本發明更相關於本發明化合物或其醫藥上可接受鹽類與細胞生長激素,或細胞激素功能性協同劑或拮抗劑(包括作用於細胞生長激素訊息路徑之藥劑,例如SOCS系統調節劑)之組合,該協同劑或拮抗劑包括α-、β-與γ-干擾素;第一型類胰島素生長因子(IGF-1);介白素(IL),包括IL1至17,與介白素拮抗劑或抑制劑,例如阿那白滯素(anakinra);腫瘤壞死因子α(TNF-α)抑制劑,例如抗-TNF單株抗體(例如因福立美(infliximab);阿達力美(adalimumab)與CDP-870)與TNF受體拮抗劑,包括免疫球蛋白分子(例如依那西普(etanercept))及低分子量藥劑,例如戊氧菲林(pentoxyfylline)。
此外,本發明係相關於本發明化合物或其醫藥上可接受之鹽類與標靶B淋巴球之單株抗體(例如CD20(瑞圖西美(rituximab))、MRA-aIL16R與T-淋巴球、CTLA4-Ig、HuMax I1-15)之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類與趨化激素受體功能調節劑,例如CCR1、CCR2、CCR2A、CCR2B、CCR3、CCR4、CCR5、CCR6、CCR7、CCR8、CCR9、CCR10與CCR11(針對C-C家族);CXCR1、CXCR2、CXCR3、CXCR4與CXCR5(針對C-X-C家族)及CX3
CR1(針對C-X3
-C家族)之拮抗劑,之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類與間質金屬蛋白酶(MMPs),亦即基質溶解素(stromelysins)、膠原蛋白酶與膠分解酶(gelatinases),以及蛋白聚糖酶(aggrecanase)等之抑制劑;特別是膠原蛋白酶-1(MMP-1)、膠原蛋白酶-2(MMP-8)、膠原蛋白酶-3(MMP-13)、基質溶解素-1(MMP-3)、基質溶解素-2(MMP-10)與基質溶解素-3(MMP-11)及MMP-9與MMP-12,包括四環黴素試劑,之組合。
本發明更相關於以本發明化合物或其醫藥上可接受鹽類與白三烯(leukotrienes)生合成抑制劑、5-脂氧化酶(5-LO)抑制劑或5-脂氧化酶活化蛋白(FLAP)拮抗劑,例如齊留通(zileuton);ABT-761;芬留通(fenleuton);地帕西(tepoxalin);Abbott-79175;Abbott-85761;N-(5-取代)-噻吩-2-烷基磺醯胺;2,6-二-第三-丁基酚腙;甲氧基四氫吡喃,例如Zeneca ZD-2138;化合物SB-210661;吡啶基-取代2-氰基萘化合物,例如L-739,010;2-氰基喹啉化合物,例如L-746,530;或吲哚或喹啉化合物,例如MK-591、MK-886與BAY x 1005,之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類與白血球間素(LT)B4、LTC4、LTD4與LTE4之受體拮抗劑,係選自於酚噻嗪-3-基,例如L-651,392;胺基化合物,例如CGS-25019c;苯噁胺,例如昂唑司特(ontazolast);苯甲醯胺,例如BIIL 284/260;以及化合物如薩福盧卡(zafirlukast)、阿普卡(ablukast)、蒙特盧卡(montelukast)、普昂盧卡(pranlukast)、凡盧卡(verlukast)(MK-679)、RG-12525、Ro-245913、依拉盧卡(iralukast)(CGP 45715A)與BAY x 7195所組成之族群,之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類與磷酸二酯酶(PDE)抑制劑,例如甲基黃原質,包括茶鹼與胺非林(aminophylline);選擇性PDE異構酶抑制劑,包括PDE4抑制劑,係異構型PDE4D之抑制劑,或PDE5抑制劑,之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類與組織胺第一型受體拮抗劑,例如西特辛(cetirizine)、羅他定(loratadine)、地所羅他定(desloratadine)、菲所芬那定(fexofenadine)、阿伐司汀(acrivastine)、特芬那定(terfenadine)、阿司咪唑(astemizole)、阿拉司汀(azelastine)、左卡巴司汀(levocabastine)、氯苯那敏(chlorpheniramine)、察異丙嗪(promethazine)、賽克利嗪(cyclizine),或咪唑司汀(mizolastine),之組合;係口服、局部或非經腸胃使用。
本發明更相關於本發明化合物或其醫藥上可接受鹽類與質子幫浦抑制劑(例如歐米普唑(omeprazole))或胃保護型組織胺第二型受體拮抗劑,之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類,與組織胺第四型受體拮抗劑之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類,與α-1/α-2腎上腺素受體協同劑血管收縮擬交感神經藥劑(vasoconstrictor sympathomimetic agent),例如丙己君(propylhexedrine)、苯腎上腺素、苯基丙醇胺、麻黃素(ephedrine)、偽麻黃素(pseudoephedrine)、萘甲唑啉氯化氫、羥甲唑啉氯化氫、四氫唑啉氯化氫、二甲苯甲唑啉氯化氫、曲馬唑啉(tramazoline)氯化氫或乙基正腎上腺素氯化氫,之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類,與抗膽鹼激導性劑,包括蕈毒鹼受體(muscarinic receptor;M1、M2與M3)拮抗劑,例如阿托品(atropine)、東莨菪鹼(hyoscine)、甘吡咯酸鹽(glycopyrrrolate)、異丙托溴銨(ipratropium bromide)、噻托溴銨(tiotropium bromide)、氧托溴銨(oxitropium bromide)、哌崙西平(pirenzepine)或泰樂西平(telenzepine),之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類,與β-腎上腺素受體協同劑(包括β受體第1-4型),例如異丙腎上腺素(isoprenaline)、沙丁胺醇(salbutamol)、福莫特羅(formoterol)、沙美特羅(salmeterol)、特布他林(terbutaline)、奧西納林(orciprenaline)、甲磺酸比拖特羅(bitolterolmesylate),或吡布特羅(pirbuterol),或其對掌鏡像異構物,之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類,與色酮(chromone),例如色甘酸鈉(sodium cromoglycate)或奈米多羅鈉(nedocromil sodium)之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類與細胞核內荷爾蒙受體,如PPARs之調控藥劑,之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類,與免疫球蛋白(lg)或Ig製備物或拮抗劑或Ig功能調節抗體,例如抗-IgE(例如歐馬紮美(omalizumab)),之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類,與另一全身性或局部應用之抗發炎藥劑,例如沙力竇邁(thalidomide)或其衍生物,視黃醇(retinoid)、二羥基蒽酚(dithranol)或鈣泊三醇(calcipotriol),之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類,與胺柳酸(aminosalicylates)與磺胺吡啶,例如柳氮磺吡啶(sulfasalazine)、美沙拉嗪(mesalazine)、巴柳氮(balsalazide),與歐沙拉嗪(olsalazine);以及免疫調節劑,例如硫嘌呤類(thiopurines),之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類,與抗菌劑,例如盤尼西林衍生物、四環黴素、大環內酯(macrolide)、β-內醯胺、氟喹啉酮、甲硝唑(metronidazole)、吸入性胺基葡萄醣苷;抗病毒試劑,包括無環鳥苷(acyclovir)、凡樂(famciclovir)、伐昔韋洛(valaciclovir)、甘席韋洛(ganciclovir)、西多夫韋(cidofovir)、金剛胺(amantadine)、金剛乙胺(rimantadine)、瑞巴凡(ribavirin)、紮那馬(zanamavir)與歐達馬(oseltamavir);蛋白酶抑制劑,例如印地那韋(indinavir)、納福那韋(nelfinavir)、瑞他那韋(ritonavir)與撒昆那韋(saquinavir);核苷酸反轉錄酶抑制劑,例如去羥肌苷(didanosine)、拉脈優錠(lamivudine)、司達優錠(stavudine)、札西他賓(zalcitabine)或季朵優錠(zidovudine);或非核苷酸反轉錄酶抑制劑,例如尼韋拉平(nevirapine)或依伐韋倫(efavirenz),之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類,與心血管藥劑,例如鈣離子通道阻斷劑、β-腎上腺素受體阻斷劑、血管收縮素轉化酶(ACE)抑制劑、血管收縮素-2受體拮抗劑;降脂劑,例如司他丁(statin)或纖維酸鹽(fibrate);血球細胞型態調節劑,例如己酮茶鹼(pentoxyfylline);血栓溶解劑,或抗凝血劑,例如血小板凝集抑制劑,之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類,與CNS藥劑,例如抗抑鬱劑(例如舍曲林(sertraline))、抗巴金森氏症藥物(例如丙炔苯丙胺(deprenyl)、L-多巴、羅匹尼羅(ropinirole)、普拉克所(pramipexole)、MAOB抑制劑,例如撒拉金(selegine)與拉賽格林(rasagiline)、comP抑制劑,例如他司馬(tasmar)、A-2抑制劑、多巴胺再吸收抑制劑、NMDA拮抗劑、尼古丁協同劑、多巴胺協同劑或神經性一氧化氮合成酶抑制劑),或抗阿茲海默氏症藥物,例如多尼潘(donepezil)、瑞他斯脈(rivastigmine)、他可寧(tacrine)、COX-2抑制劑、丙酮茶鹼(propentofylline)或美曲磷脂(metrifonate),之組合。
本發明更相關於以本發明化合物或其醫藥上可接受鹽類,與治療急性或慢性疼痛藥劑,例如中樞或周邊作用鎮痛劑(例如鴉片鹼或其衍生物)、卡馬西平(carbamazepine)、芬尼同(phenytoin)、丙戊酸鈉、阿米替林(amitryptiline)或其他抗抑鬱劑、對乙醯基胺基酚(paracetamol),或非固醇類抗發炎藥劑,之組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類,與非口服或局部應用(包括吸入型)之局部麻醉劑,例如力諾卡因(lignocaine)或其衍生物,之組合。
本發明化合物或其醫藥上可接受鹽類,亦可與抗骨質疏鬆藥劑,包括荷爾蒙藥劑,例如拉羅斯芬(raloxifene),或雙磷酸鹽(biphosphonate),例如阿倫膦酸鹽(alendronate)組合。
本發明更相關於本發明化合物或其醫藥上可接受鹽類與:(i)胰蛋白酶(tryptase)抑制劑;(ii)血小板活化因子(PAF)拮抗劑;(iii)介白素轉化酶(ICE)抑制劑;(iv)IMPDH抑制劑;(v)黏著分子抑制劑,包括VLA-4拮抗劑;(vi)細胞自溶酵素(cathepsin);(vii)激酶抑制劑,例如酪胺酸激酶抑制劑(例如Btk、Itk、Jak3或MAP,例如吉菲替尼(Gefitinib)或依馬替尼(Imatinib)甲磺酸鹽)、絲胺酸/蘇胺酸激酶抑制劑(例如,MAP激酶如p38、JNK、蛋白激酶A、B或C,或IKK之抑制劑),或參與調節細胞週期之激酶(例如周期素依賴性激酶);(viii)葡萄糖-6-磷酸鹽去氫酶抑制劑;(ix)激肽(kinin)-B1
-或B2
-受體拮抗劑;(x)抗痛風劑,例如秋水仙素(colchicine);(xi)黃原質(xanthine)氧化酶抑制劑,例如安洛普諾(allopurinol);(xii)促尿酸排泄劑(uricosuric agent),例如彼洛喜(probenecid)、苯磺唑酮(sulfinpyrazone)或磺吡酮或苯溴馬龍(benzbromarone);(xiii)生長激素促泌素;(xiv)變形生長因子(TGFβ);(xv)血小板源生長因子(PDGF);(xvi)纖維母細胞生長因子,例如鹼性纖維母細胞生長因子(bFGF);(xvii)顆粒球巨嗜細胞聚落刺激因子(granulocyte macrophage colony stimulating factor;GM-CSF);(xviii)辣椒素乳膏(capsaicin cream);(xix)速激肽(tachykinin) NK1
或NK3
受體拮抗劑,例如NKP-608C、SB-233412(托內登(talnetant))或D-4418;(xx)彈性蛋白酶抑制劑,例如UT-77或ZD-0892;(xxi)TNF-α轉化酶抑制劑(TACE);(xxii)誘發型一氧化氮合成酶(iNOS)抑制劑;(xxiii)化學引誘劑受器-同源分子表達於TH2細胞,(例如CRTH2拮抗劑);(xxiv)P38抑制劑;(xxv)類鐸受體(Toll-like receptors;TLR)功能調節劑;(xxvi)嘌呤受體(purinergic receptors)活性調節劑,例如P2X7;(xxvii)轉錄因子活化抑制劑,例如NFkB、API或STATS;或(xxviii)腎上腺醣皮質激素受體協同劑,組合。
在本發明之另一觀點中,係提供(固定劑量)如前面所定義之本發明化合物或其醫藥上可接受鹽類,與一或更多藥劑(例如用於治療COPD、氣喘或過敏性鼻炎者)之組合,該藥劑係獨立地選自於:
● 選擇性β2
腎上腺素受體協同劑(例如奧西普那林(metaproterenol)、異丙特醇(isoproterenol)、異丙腎上腺素(isoprenaline)、奧丁胺醇(albuterol)、沙丁胺醇(salbutamol)、福莫特羅(formoterol)、沙美特羅(salmeterol)、特布他林(terbutaline)、奧西納林(orciprenaline)、甲磺酸比拖特羅(bitolterol mesylate)、吡布特羅(pirbuterol)或因塔特羅(indacaterol));
● 磷酸二酯酶抑制劑(例如PDE4抑制劑);
● 蛋白酶抑制劑(例如嗜中性白血球彈性酵素或基質金屬蛋白酶MMP-12抑制劑);
● 抗膽鹼激素藥劑;
● 趨化激素受體功能調節劑(例如CCR1受體拮抗劑);以及
● 激酶功能抑制劑(例如p38激酶或IKK);
以及任擇地一或多種醫藥上可接受之賦形劑。
本發明亦提供一種醫藥產品,包含有一第一活性成分製劑,其為如前述定義之本發明化合物或其醫藥上可接受鹽類,以及一第二活性成分製劑,其為:
● 選擇性β2
腎上腺素受體協同劑;
● 磷酸二酯酶抑制劑;
● 蛋白酶抑制劑;
● 抗膽鹼激素藥劑;
● 趨化激素受體功能調節劑;以及
● 激酶功能抑制劑;
其中本發明製備物係同時、依序或個別投至有需要之病患。
在另一觀點中,本發明係提供一種套組,包含有一第一活性成分製劑,其為如前述定義之本發明化合物或其醫藥上可接受鹽類,以及一第二活性成分製劑,其為:
● 選擇性β2
腎上腺素受體協同劑;
● 磷酸二酯酶抑制劑;
● 蛋白酶抑制劑;
● 抗膽鹼激素藥劑;
● 趨化激素受體功能調節劑;以及
● 激酶功能抑制劑;
以及用於同時、依序或個別投予該製劑至有需要病患之用藥指示。
本發明化合物或其醫藥上可接受鹽類,亦可與現今之癌症治療藥物組合,例如適用之藥劑包括:
(i)抗增生/抗腫瘤藥物或其組合物,如用於內科腫瘤學,例如烷化劑(例如用於醫療腫瘤學,如烷基化試劑(如順鉑、卡鉑(carboplatin)、環磷醯胺、硝基化芥氣、威克瘤(melphalan)、苯丁氯氮芥(chlorambucil)、白消安(busulphan)或硝基尿素);抗代謝物(如抗葉酸,如氟嘧啶類似物5-氟脲嘧啶或替加福(tegafur)、雷替曲賽(raltitrexed)、甲氨蝶呤、阿糖胞苷(cytosine arabinoside)、羥基尿素、金賽他賓(gemcitabine)紫杉醇(paclitaxel));抗腫瘤抗生素(如蒽環類如阿黴素(adriamycin)、平陽黴素(bleomycin)、去氧比星(doxyrubicin)、道諾黴素(daunomycin)、表柔比星(epirubicin)、依達比星(idarubicin)、絲裂黴素(mitomycin)-C、達汀黴素(dactinomycin)或米拉黴素(mithramycin));抗有絲分裂試劑(例如如長春花生物鹼(vinca alkaloid)如長春新鹼(vincristine)、長春鹼(vinblastine)、長春地新(vindesine)或長春瑞濱(vinorelbine),或石斛鹼(taxoid)如汰癌勝(taxol)或泰所地(taxotere));或拓樸異構酶抑制劑(例如表鬼臼毒素(epipodophyllotoxin),如依托伯苷(etoposide)、替尼伯苷(teniposide)、胺苯吖啶(amsacrine)、托伯替康(topotecan)或喜樹鹼(camptothecin));
(ii)細胞生長抑制藥劑,例如抗雌激素(例如他莫斯芬(tamoxifen)、拓瑞米芬(toremifene)、拉羅西芬(raloxifene)、卓羅西芬(droloxifene)或碘西芬(iodoxyfene))、雌激素受體向下調控劑(例如復維司卓(fulvestrant))、抗雄性激素(例如比卡魯胺(bicalutamide)、氟它醯胺(flutamide)、尼路醯胺(nilutamide)或環丙孕酮(cyproterone)醋酸鹽)、LHRH拮抗劑或LHRH協同劑(例如戈舍瑞林(goserelin)、魯普瑞林(leuprorelin)或布舍瑞林(buserelin))、牛孕酮(progestogen)(例如甲地孕酮(megestrol)醋酸鹽)、芳香酶抑制劑(例如瑞寧得(anastrozole)、來曲唑(letrozole)、伏率唑(vorazole)或伊美西坦(exemestane))或5α-還原酶抑制劑,例如柔沛(finasteride);
(iii)可抑制癌細胞入侵之試劑(如金屬蛋白酶抑制劑如,美瑞馬坦(marimastat)或尿激酶血纖維蛋白溶解酶活化劑受體功能抑制劑);
(iv)生長因子功能抑制劑,如:生長因子抗體(如抗-erb b2抗體曲妥珠美(trastuzumab),或抗-erb b1抗體西圖司美(cetuximab)[C225]),法呢基(farnesyl)轉移酶抑制劑,酪胺酸激酶抑制劑,或絲胺酸/蘇胺酸激酶抑制劑,內皮生長因子家族抑制劑(如EGFR家族酪胺酸激酶抑制劑,例如N
-(3-氯-4-氟苯基)-7-甲氧基-6-(3-嗎啉丙氧基)喹唑啉-4-胺(金菲替尼(gefitinib)、AZD1839)、N-(3-乙炔苯基)-6,7-雙(2-甲氧基乙氧基)喹唑啉-4-胺(而羅替尼(erlotinib),OSI-774),或6-丙烯醯胺-N-(3-氯-4-氟苯基)-7-(3-嗎啉丙氧基)喹g啉-4-胺(CI 1033)),血小板-衍生生長因子家族抑制劑,或肝細胞生長因子家族抑制劑;
(v)抗血管新生試劑,如可抑制血管內皮生長因子作用者(如抗-血管內皮細胞生長因子抗體,倍伐西美(bevacizumab),揭示於WO 97/22596、WO 97/30035、WO 97/32856或WO 98/13354之化合物),或經由另一機制作用之化合物(如三羧氨基喹啉(linomide)、整合素(integrin)αvβ3功能抑制劑或血管生成抑制素(angiostatin));
(vi)血管傷害試劑如康伯斯坦(combretastatin)A4,或揭示於WO 99/02166、WO 00/40529、WO 00/41669、WO 01/92224、WO 02/04434或WO 02/08213者;
(vii)用於反義股療法(antisense therapy)之試劑,例如導向上述標的基因之一者,如ISIS 2503標靶者,一抗-ras反義股;
(viii)用於基因療法之試劑,如置換不正常基因之療法,如不正常之p53或不正常之BRCA1或BRCA2、GDEPT(基因-引導酵素前驅藥物療法)法,如使用於胞嘧啶去胺基酶、胸腺嘧啶激酶或細菌硝基還原酶酵素法,以增進病患對於化學療法或放射療法之耐受度,如多重抗藥性基因療法;或
(ix)用於免疫療法之試劑,如體外與體內之方法,增進病患腫瘤細胞之免疫性,如轉染細胞激素如介白素2、介白素4,或顆粒細胞巨噬體群落刺激因子、降低T-細胞反應低落法、使用轉染免疫細胞法如細胞激素-轉染樹突細胞法、使用細胞激素-轉染腫瘤細胞株法,以及使用抗原發性抗體法。
本發明將以下列範例進行更進一步之說明,使用下列縮寫:
EtOAc 乙酸乙酯
HCl 氫氯酸
H2
S 硫化氫
CH2
Cl2
二氯甲烷(DCM)
DMF N,N
-二甲基甲醯胺
NaH 氫化鈉
MgSO4
硫酸鎂
NaNO2
亞硝酸鈉
K2
CO3
碳酸鉀
SnCl2
氯化錫(II)
NaOH 氫氧化鈉
Na2
SO4
硫酸鈉
NH4
Cl 氯化銨
DIEA 二異丙基乙胺
DME 二甲醚
DCM 二氯甲烷
DMSO 二甲基亞碸
EtOH 乙醇
Et2
O 乙醚
THF 四氫呋喃
TFA 三氟醋酸
HCl 氫氯酸
NaHCO3
碳酸氫鈉
Et3
N 三乙胺
MeOH 甲醇
MeCN/ 乙腈
CH3
CN
EDTA 乙烯二胺四醋酸
NMP N-甲基吡咯烷
conc. 經濃縮
rt...室溫
h...小時
min...分鐘
M...莫耳濃度
MS...質譜學
APCI...大氣化學離子化法
ESI...電灑離子化法
NMR...核磁共振
SCX...使用硫酸吸附劑之固相萃取
HPLC...高效能液相層析儀
LC-MS...使用質譜偵測之液相層析儀
NMR光譜係以Varian Mercury-VX 300 MHz儀器或Varian Inova 400MHz儀器紀錄。氯仿-d
(H 7.26 ppm)、丙酮-d 6
(H 2.05 ppm)、乙腈-d 3
(δH
1.94 ppm)或DMSO-d 6
(H 2.50 ppm)之中央尖峰係用於作為內標準品。
下列方法係用於進行LC/MS分析:儀器Agilent 1100;管柱為Waters Symmetry 2.1 x 30 mm;Mass APCI;流速0.7 mL/分鐘;波長254 nm;溶劑A:水+0.1% TFA;溶劑B:乙腈+0.1% TFA;梯度15-95%/B2.7分鐘,95% B 0.3分鐘。
管柱層析法係使用矽膠管柱(0.040-0.063 mm,Merck)。
就製備級HPLC而言,不論是KR-100-5-C18管柱(250 x 20 mm,Akzo Nobel),以及乙腈/水(0.1% TFA)混合物,流速為10 ml/分鐘,或是Prep MS C18
OBDTM
管柱,5μm,19 x 50 mm(乙腈/水/0.1% NH3
),流速為20 ml/分鐘,皆可使用。UV=254 nm或220 nm係用於偵測。
除非另有說明,起始物質皆為商業上可購得。所有溶劑與市售試劑皆為實驗室等級,並於到貨時立即使用。
在1000 mL圓底錐形瓶中,地塞米松(dexamethasone)(10 g,25.48 mmol)懸浮於EtOAc(400 mL)與乙醇(100 mL)中,並加入三(三苯基膦)氯化銠(I)(威爾金森催化劑(Wilkinson's catalyst),2.5 g,2.70 mmol),使用磁性攪拌子。混合物於室溫之氫氣環境下(1 atm)劇烈攪拌1週,並加入另外1.0 g催化劑。反應繼續進行一週,所得混合物於真空下濃縮,得固體,懸浮於DCM中(100 ml),懸浮液經過濾。所得固體以三部分DCM(50 ml)清洗,並於燒結機(sinter)中風乾,得9.6 g目標化合物,係灰白色固體。APCI-MS m/z: 395[MH+
]。
在500 mL圓底錐形瓶中,中間產物1(9.5 g,24.08 mmol)溶於THF(200 mL),並於室溫下加入80 ml之過碘酸(10.98 g,48.17 mmol)水溶液。所得混合物於相同溫度下攪拌2小時,真空下移除有機溶劑,所得濕式漿液經水稀釋(100 ml)。所得固體經過濾、於濾紙上以水清洗,並於燒結機中風乾,得9.0 g灰白色希望之產物。APCI-MS m/z: 381[MH+
]。
在1000 mL圓底錐形瓶中,配備磁性攪拌子與迴流冷凝器,加入氫化鈉(60%溶於礦物油中,10.32 g,236.56 mmol)與無水THF(150 mL),產生白色懸浮物,並於室溫氬氣環境下攪拌。依序加入中間產物2(9 g,23.66 mmol)與甲酸乙酯(96 mL,1182.81 mmol),所得混合物於相同溫度下攪拌約2小時。小心地加入2M NaOH(50 ml)以中止反應,所得混合物攪拌5分鐘,並隨即移至一分液漏斗中,使各相分離。收集水相,有機相以40 ml之2M NaOH萃取。合併之水相以水(50 ml)稀釋、以Et2
O(50 ml)清洗,並以4M HCl(90 ml)酸化。產物以EtOAc(2x150 ml)萃取,合併之有機相以飽和食鹽水(100 ml)清洗,並以Na2
SO4
除水。有機相經過濾,並於真空下揮發,得7.2 g所希望之橙色泡沫體,直接用於下一步驟而不另進行任何純化。APCI-MS m/z: 409[MH+
]。
在500mL圓底錐形瓶中,中間產物3(7.2 g,17.63 mmol)溶於醋酸(100 mL),且溶液以氮氣N2
進行除氣。室溫下加入2-氟-5-肼基吡啶(2.465 g,19.39 mmol),混合物以磁性攪拌子攪拌30分鐘。溶液經冷凍乾燥至隔日,產生8.7g所希望之產物,為橙色固體。APCI-MS m/z: 500[MH+
]。
在100 mL圓底錐形瓶中,中間產物4(8.7 g,17.62 mmol)溶於DMF(20 mL),並於室溫下加入二(1H-咪唑-1-基)甲酮(CDI,5.71 g,35.23 mmol)。待氣體排放完畢,該混合物係攪拌於密封錐形瓶中至隔日。之後灌入硫化氫(H2
S)使溶液產生氣泡10分鐘,所得溶液繼續攪拌10分鐘。溶液於分液漏斗中加至200 ml 1M HCl中,混合物以EtOAc(2x150 ml)萃取。合併之有機相以0.5 M HCl(3x100 ml)與飽和食鹽水(40 ml)清洗,隨即以Na2
SO4
除水、過濾,有機溶劑於真空下揮發,得9.0 g希望之產物,為橙色泡沫體,用於下一步驟而不另進行任何純化。APCI-MS m/z: 516[MH+
]。
在50 mL圓底錐形瓶中,將中間產物5(0.1 g,0.19 mmol)與三乙基胺(0.067 mL,0.48 mmol)溶於DCM(10 mL)中,並於室溫下加入丙醯氯(0.038 g,0.41 mmol)。持續攪拌10分鐘。加入N 1
-乙基-N 2
,N 2
-二甲基乙烷-1,2-二胺(0.091 mL,0.58 mmol),且混合物於相同溫度下繼續攪拌10分鐘。反應混合物以DCM稀釋至總體積25 ml,所得混合物以1M HCl(2x20 ml)與飽和食鹽水清洗(10 ml)。有機相以Na2
SO4
除水,濾除乾燥劑,有機溶劑於真空下揮發,得99 mg希望之化合物,為黃色半固體狀。APCI-MS m/z:572[MH+
]。
此化合物係依據中間產物6所描述之流程製備,並起始於中間產物5。APCI-MS m/z: 611[MH+
]。
此化合物係依據中間產物5所描述之相同流程製備。APCI-MS m/z: 515[MH+
]。
在250 mL圓底錐形瓶中,將(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-二羥基-17-(2-羥基乙醯基)-6,10,13-三甲基-6,7,8,9,10,11,12,13,14,15,16,17-十二氫-3H-環戊[a]菲-3-酮(6α-甲基普地索隆(6α-methylprednisolon),4.3 g,11.48 mmol)懸浮於EtOAc(80 mL)且反應混合物以乙醇(20.0 mL)稀釋。加入三(三苯基膦)氯化銠(I)(威爾金森催化劑,1 g,1.08 mmol)與磁性攪拌子,反應錐形瓶於室溫氫氣環境下(1atm)劇烈攪拌一週。反應混合物以玻璃過濾漏斗過濾之,濾液於真空下濃縮,得4.07 g希望之化合物,為淡棕色固體,用於下一步驟而不另進行任何純化。APCI-MS m/z: 377[MH + ]。
此化合物係依據中間產物2所描述之流程製備,並起始於中間產物9。APCI-MS m/z: 363[MH+
]。
此化合物係依據中間產物3所描述之流程製備,並起始於中間產物10。APCI-MS m/z: 391[MH+
]。
此化合物係依據中間產物4所描述之流程製備,並起始於中間產物11。APCI-MS m/z: 482[MH+
]。
此化合物係依據中間產物5所描述之流程製備,並起始於中間產物12。APCI-MS m/z: 498[MH+
]。
此化合物係依據中間產物6所描述之流程製備,並起始於中間產物13。APCI-MS m/z: 554[MH+
]。
此化合物係依據中間產物6所描述之流程製備,並起始於中間產物13。APCI-MS m/z: 570[MH+
]。
此化合物係依據中間產物6所描述之流程製備,並起始於中間產物13。APCI-MS m/z: 593[MH+
]。
此化合物係依據中間產物6所描述之流程製備,並起始於中間產物13。APCI-MS m/z: 566[MH+
]。
在1000 mL圓底錐形瓶中,將2-((8S,9R,10S,11S,13S,14S,17R)-9-氟-11,17-二羥基-10,13-二甲基-3-氧代-2,3,6,7,8,9,10,11,12,13,14,15,16,17-十四氫-1H-環戊[a]菲-17-基)-2-氧乙基醋酸酯(氟氫可的松(Fludrocortisone)-21-醋酸酯,22.8 g,53.97 mmol)懸浮於MeOH(200 mL)中,懸浮物以氮氣除氣。將2M氫氧化鈉(40.5 mL,80.95 mmol)加入溶液中,混合物攪拌10分鐘。溶液中加入4M HCl(20 ml,80 mmol)並於真空下移去MeOH。所得殘餘物溶於THF(200 ml),室溫下加入正過碘酸(15.99 g,70.16 mmol)之水溶液(40 ml),所得混合物攪拌1小時。加入100 ml水,且有機溶劑於真空下移除。另外加入100 ml水於水性殘餘物中,所得固體以過濾法收集、以清水(2x200 ml)清洗,並於燒結機中風乾,接著於真空下乾燥之,得20g希望之化合物,為灰白色固體。APCI-MS m/z: 367[MH+
]。
在攪拌之氫化鈉(6.55 g,272.91 mmol)之THF(130 mL)懸浮液(10.9 g,60%懸浮於礦物油)中,分2-3次加入中間產物18(10 g,27.29 mmol),隨後加入甲酸乙酯(111 mL,1364.54 mmol)。混合物於室溫氬氣環境下攪拌約2小時。仔細地加入2M NaOH(50 ml)中止反應,各相分離出。有機相係以額外之2x20 ml 2M NaOH萃取。合併之水相以水(15 ml)稀釋、經Et2
O(40 ml)清洗,並以4M HCl酸化。產物以EtOAc(3x100 ml)萃取,合併之有機相以飽和食鹽水(30 ml)清洗、Na2
SO4
除水,過濾並於真空下揮發,得8.6 g希望之產物,為橙色半固體,直接用於下一步驟而不另進行任何純化。APCI-MS m/z: 395[MH+
]。
在500 mL圓底錐形瓶中,將中間產物19(10 g,25.35 mmol)溶於醋酸(100 mL)中,溶液以氮氣除氣5分鐘。室溫下加入2-氟-5-肼基吡啶(3.22 g,25.35 mmol),所得混合物攪拌15分鐘。所得溶液經冷凍乾燥至隔日,且所得材料懸浮於EtOAc中(40 ml),並於室溫下另外攪拌10分鐘。所得固體以過濾方式分離,以EtOAc(10 ml)清洗,最後於玻璃過濾漏斗上以氣流乾燥之,得6.9 g固體希望之產物。APCI-MS m/z: 486[MH+
]。
此化合物係依據中間產物5所描述之流程製備,並起始於中間產物20。APCI-MS m/z: 502[MH+
]。
將中間產物21(0.3 g,0.6 mmol)溶於DCM(10 ml),並於室溫下加入三乙基胺(0.165 ml,1.2 mmol)。混合物預先攪拌3分鐘,再分次加入(R
)-四氫呋喃-2-羰基氯化物(J. Chem. Soc,Perkin Trans. 1,2002,571-576)(0.15g,1.2mmol)之DCM(1 ml)溶液,混合物繼續攪拌15分鐘。加入N 1
-乙基-N 2
,N 2
-二甲基乙烷-1,2-二胺(0.305 ml,2.04 mmol),混合物繼續攪拌20分鐘。混合物以DCM(20 ml)稀釋,以2N HCl(2次20 ml)、飽和食鹽水清洗,並以硫酸鈉除水。經過濾後,溶劑減壓揮發,得0.4 g粗產物,直接使用而不另進行任何純化。APCI-MS m/z: 600[MH+
]。
此化合物係依據中間產物22所描述之流程製備,並起始於中間產物21。APCI-MS m/z: 600[MH+
]。
此化合物係依據中間產物22所描述之流程製備,並起始於中間產物21。APCI-MS m/z: 600[MH+
]。
在1000 mL圓底錐形瓶中,將(8S,9S,10R,11S,13S,14S,17R)-11,17-二羥基-17-(2-羥基乙醯基)-10,13-二甲基-6,7,8,9,10,11,12,13,14,15,16,17-十二氫-1H-環戊[a]菲-3(2H)-酮(10.4 g,28.69 mmol)懸浮於MeOH中(200 mL),並加入正過碘酸(9.81 g,43.04 mmol)之水溶液(200 mL),得無色溶液。混合物攪拌45分鐘後,另外加入3 g正過碘酸,繼續攪拌一小時。真空下移除MeOH,殘餘水性混合物以200ml水稀釋。所得固體以過濾法分離,並於燒結機中風乾,得8.1 g希望之化合物,為白色固體。APCI-MS m/z: 349[MH+
]。
攪拌中之氫化鈉(5.73 g,143.5 mmol,60%懸浮於礦物油)之THF(100 ml)懸浮液,於氬氣下小量加入中間產物25(5.00 g,14.35 mmol)。5分鐘後,加入甲酸乙酯(58.4 ml,717.5 mmol),並於室溫下持續攪拌至隔日。混合物以甲酸中止反應,得一黏稠懸浮液,並加入NaOH水溶液(2M,50 ml)。混合物於室溫下攪拌10分鐘,各相分離出,移除有機相。水相以濃HCl水溶液酸化,並以乙酸乙酯(3次50 ml)萃取。合併之有機相以硫酸鈉除水、過濾,溶劑減壓揮發,得目標化合物(5.65 g),為黃色固體。APCI-MS m/z: 377[MH+
]。
將中間產物26(4.2 g,11.16 mmol)溶於醋酸(30 mL)中,加入(4-氟苯基)肼氯化氫(2.177 g,13.39 mmol),接著加入醋酸鈉(0.783 mL,14.50 mmol),最後以水(8ml)稀釋。於室溫下攪拌2小時後,混合物於真空下濃縮,將液體殘餘物倒入EtOAc(200 ml)與水(150 ml)中。移出水相,有機相以2M NaOH(3x90 ml)清洗,合併之水相經酸化並以EtOAc(3次100 ml)萃取。合併之有機相以飽和食鹽水(100 ml)清洗,Na2
SO4
除水,並真空濃縮,得4.2g目標化合物,為淡棕色泡沫體。APCI-MS m/z: 467[MH+
]。
在25 mL圓底錐形瓶中,將中間產物27(0.2 g,0.43 mmol)溶於DMF(3 ml),並加入1,1-羰基二咪唑(0.139 g,0.86 mmol)。所得溶液於室溫下攪拌至隔日。以H2
S(g)使溶液產生氣泡5分鐘,混合物繼續攪拌30分鐘。將反應混合物倒入1M HCl(15 ml),所得固體部分以過濾法分離,以清水清洗並乾燥之,得0.2 g希望之粗產物,用於下一步驟而不另進行任何純化。APCI-MS m/z: 483[MH+
]。
此化合物係製備自中間產物28與四氫呋喃-2-羰基氯化物(J. Chem. Soc,Perkin Trans. 1,2002,571-576),依據中間產物22所描述之流程製備。APCI-MS m/z: 581[MH+
]。
將中間產物20(0.1 g,0.21 mmol)溶於DCM(4mL),加入三乙基胺(0.09 ml,0.65 mmol),混合物攪拌5分鐘後,室溫下加入環戊烷羰基氯化物(0.035 ml,0.39 mmol)之DCM溶液(1ml),混合物攪拌30分鐘。加入N 1
,N 1
,N 2
-三甲基乙烷-1,2-二胺(0.12 ml,0.94 mmol),混合物於相同溫度下繼續攪拌25分鐘。反應混合物以DCM(10 ml)稀釋,並以1M HCl(2x10 ml)與飽和食鹽水(20 ml)清洗。有機相以Na2
SO4
除水,過濾,並於真空下揮發,得110 mg目標化合物。APCI-MS m/z: 554[MH+
]。
此化合物係依據中間產物27與中間產物30所描述之流程製備,並起始於中間產物26與環戊烷羰基氯化物。APCI-MS m/z: 536[MH+
]。
此化合物係依據中間產物6所描述之流程製備,並起始於中間產物13。APCI-MS m/z: 592[MH+
]。
在250 mL圓底錐形瓶中,將中間產物5(8.8 g,17.07 mmol)溶於DCM(80 mL),並加入三乙基胺(5.91 mL,42.67 mmol)。將2-甲氧基乙醯基氯化物(3.89 g,35.84 mmol)加入經攪拌混合物中,隨後於水浴槽中冷卻,且混合物攪拌10分鐘。加入N 1
-乙基-N 2
,N 2
-二甲基乙烷-1,2-二胺(3.48 mL,22.19 mmol),混合物繼續攪拌10分鐘。加入60%溴氟甲烷(4.82 g,25.60 mmol)之DMF溶液,接著加入三乙基胺(2 ml),反應繼續攪拌30分鐘。所得混合物於真空下濃縮,並於EtOAc(150 ml)與1M HCl(150 ml)中分層。水相以EtOAc(150 ml)萃取,且合併之有機相以0.5M HCl(2x100 ml)、清水(100 ml)與飽和食鹽水(50 ml)清洗。經Na2
SO4
除水後過濾,並於真空下揮發,得泡沫狀粗產物,以矽膠純化(庚烷:EtOAc 3:1至2:1),得2.9g目標產物,為淡黃色固體。
取小量(0.35g)本材料樣品於製備級HPLC管柱(Kromasil C18,CH3CN/水)中純化,含本化合物部分經冷凍乾燥,得0.26g目標化合物,為無色固體。將固體懸浮於Et2
O(10 ml)中,懸浮液於室溫下攪拌2小時。固體經過濾分離,得0.23g目標產物,為白色結晶固體。APCI-MS m/z: 620[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.36(1H,s),7.99(1H,m),7.51(1H,s),7.07(1H,dd),6.18(1H,s),6.01-5.76(2H,m),4.45(1H,bs),4.12(2H,s),3.45(3H,s),3.45-3.40(1H,m),3.32(1H,d),2.80(1H,d),2.61(1H,t),2.49-2.19(4H,m),1.96-1.82(2H,m),1.76-1.66(1H,m),1.65-1.51(1H,m),1.41(3H,s),1.41-1.33(1H,m),1.28(1H,bs),1.12(3H,s),1.04(3H,d)。
在小瓶中,將中間產物6(0.05 g,0.09 mmol)與N
,N
-二異丙基乙基胺(0.043 mL,0.26 mmol)溶於二噁烷中(3 mL),並於室溫下加入60%溴氟甲烷(0.033 g,0.17 mmol)之DMF溶液。混合物攪拌60分鐘,且所得粗混合物於真空下濃縮,溶於CH3
CN/水中(3ml/0.5ml),並注入製備級HPLC-管柱。含產物之部分經冷凍乾燥,得15 mg希望之化合物,為無色固體。APCI-MS m/z: 604[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.36(1H,s),7.99(1H,m),7.50(1H,s),7.07(1H,m),6.18(1H,s),6.03-5.75(2H,m),4.45(1H,bs),3.41(1H,bs),3.33(1H,d),2.81(1H,d),2.61(1H,t),2.52-2.32(5H,m),2.32-2.21(1H,m),1.96-1.80(2H,m),1.77-1.66(1H,m),1.65-1.51(1H,m),1.41(3H,s),1.41-1.32(1H,m),1.29(1H,bs),1.17(3H,t),1.10(3H,s),1.01(3H,d)。
在小瓶中,將中間產物6(0.05 g,0.09 mmol)與N
,N
-二異丙基乙基胺(0.020 mL,0.12 mmol)溶於二噁烷中(3 mL),並於室溫下加入2-溴乙腈(6.99 μL,0.10 mmol)。混合物攪拌10分鐘,揮發物於真空下移除,殘餘物懸浮於CH3
CN(3 ml)與水(1 ml)中。所得懸浮液經過濾,將溶液注入製備級HPLC-管柱。收集含產物之部分並冷凍乾燥,得8 mg希望之化合物,為無色固體。APCI-MS m/z: 611[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.36(1H,s),7.99(1H,m),7.51(1H,s),7.07(1H,dd),6.18(1H,s),4.46(1H,bs),3.72(2H,s),3.41-3.28(2H,m),2.81(1H,d),2.61(1H,t),2.48-2.31(5H,m),2.31-2.18(1H,m),1.94-1.80(2H,m),1.77-1.66(1H,m),1.65-1.51(1H,m),1.44(1H,bs),1.41(3H,s),1.41-1.32(1H,m),1.16(3H,t),1.12(3H,s),1.02(3H,d)。
此化合物係依據範例2所描述之流程製備,並起始於中間產物7。APCI-MS m/z: 643[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.37(1H,s),8.25(1H,s),7.99(1H,m),7.95(1H,s),7.51(1H,s),7.08(1H,dd),6.19(1H,s),6.05-5.74(2H,m),4.51(1H,bs),3.57-3.45(1H,m),3.37(1H,d),2.82(1H,d),2.69-2.51(2H,m),2.46-2.23(3H,m),2.03-1.85(2H,m),1.81-1.70(1H,m),1.66-1.56(1H,m),1.43(3H,s),1.42-1.32(2H,m),1.17(3H,s),1.08(3H,d)。
在50 mL圓底錐形瓶中,將中間產物8(0.09 g,0.17 mmol)與三乙基胺(0.061 mL,0.44 mmol)溶於DCM中(10 mL),並於室溫下加入丙醯氯(0.034 g,0.37 mmol)。混合物攪拌10分鐘,加入N 1
-乙基1-N 2
,N 2
-二甲基乙烷-1,2-二胺(0.082 mL,0.52 mmol),且混合物繼續攪拌10分鐘。反應混合物以DCM稀釋至總體積25 ml,所得混合物以1M HCl(2x20 ml)與飽和食鹽水(10 ml)清洗。有機層以Na2
SO4
除水,過濾並揮發,得90 mg之黃色固體(1R,2R,3aS,3bS,10aS,10bR,11S,12aS)-10b-氟-7-(6-氟吡啶-3-基)-11-羥基-2,10a,12a-三甲基-1-(丙烯基氧基)-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-羧硫代S-酸。APCI-MS m/z: 571[MH+
]。
將所得羧硫代酸(0.045 g,0.08 mmol)與N
,N
-二異丙基乙基胺(0.039 mL,0.24 mmol)溶於二噁烷(3 mL),並加入60%溴氟甲烷(0.030 g,0.16 mmol)之DMF溶液。混合物攪拌60分鐘,揮發物隨即於真空下移除。將殘餘物懸浮於CH3
CN(3 ml)與水(1 ml)之混合物中,所得懸浮液經過濾,並將溶液注入製備級HPLC-管柱。收集含產物之部分並冷凍乾燥,得15 mg希望之化合物,為無色固體。APCI-MS m/z: 603[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ7.50-7.42(3H,m),7.16(2H,t),6.18(1H,s),6.02-5.75(2H,m),4.45(1H,bs),3.41(1H,bs),3.32(1H,d),2.79(1H,d),2.59(1H,t),2.51-2.38(3H,m),2.38-2.18(3H,m),1.97-1.79(2H,m),1.75-1.65(1H,m),1.63-1.51(1H,m),1.40(3H,s),1.39-1.32(1H,m),1.32-1.27(1H,m),1.17(3H,t),1.10(3H,s),1.01(3H,d)。
在50 mL圓底錐形瓶中,將中間產物8(0.09 g,0.17 mmol)與三乙基胺(0.061 mL,0.44 mmol)溶於DCM(10 mL),並於室溫下加入2-甲氧基乙醯基氯化物(0.040 g,0.37 mmol)。混合物攪拌10分鐘,加入N 1
-乙基-N 2
,N 2
-二甲基乙烷-1,2-二胺(0.082 mL,0.52 mmol),所得混合物繼續攪拌10分鐘。反應混合物以DCM稀釋至總體積25 ml,並以1M HCl(2x20 ml)與飽和食鹽水(10 ml)清洗。有機層以Na2
SO4
除水,過濾並揮發,得105 mg之(1R,3aS,3bS,5S,10aR,10bS,11S,12aS)-7-(6-氟吡啶-3-基)-11-羥基-1-[(甲氧基乙醯基)氧基]-10a,12a-二甲基-1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-十四氫環戊[5,6]萘並[1,2-f]吲唑-1-羧硫代S-酸,為黃色固體。APCI-MS m/z: 587[MH+
]。
將所得羧硫代酸(0.05 g,0.09 mmol)與N
,N
-二異丙基乙基胺(0.042 mL,0.26 mmol)溶於二噁烷(3 mL),並於室溫下加入溶於DMF之60%溴氟甲烷(0.032 g,0.17 mmol)溶液。所得混合物攪拌60分鐘,揮發物隨即於真空下移除,殘餘物懸浮於CH3
CN(3 ml)與水(1 ml)之混合物中。懸浮液經過濾,並將溶液注入製備級HPLC-管柱。收集含產物之部分並冷凍乾燥,得12 mg希望之化合物,為白色固體。APCI-MS m/z: 619[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ7.50-7.42(3H,m),7.16(2H,t),6.17(1H,s),6.01-5.76(2H,m),4.45(1H,bs),4.12(2H,s),3.46(3H,s),3.50-3.38(1H,m),3.31(1H,d),2.78(1H,d),2.59(1H,t),2.47-2.18(4H,m),1.95-1.81(2H,m),1.75-1.64(1H,m),1.63-1.51(1H,m),1.40(3H,s),1.39-1.29(2H,m),1.11(3H,s),1.04(3H,d)。
此化合物係依據範例2所描述之流程製備,並起始於中間產物14。APCI-MS m/z: 586[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.37(1H,s),8.01(1H,m),7.49(1H,s),7.09(1H,dd),6.12(1H,s),6.06-5.61(2H,m),4.57(1H,bs),3.06-2.95(2H,m),2.77(1H,d),2.54(1H,bs),2.37(2H,m),2.18-2.06(2H,m),2.04-1.91(3H,m),1.87-1.76(1H,m),1.68-1.58(1H,m),1.54-1.41(1H,m),1.34(3H,s),1.26(1H,d),1.20-1.08(7H,m),1.01(3H,s),0.87(1H,q)。
此化合物係依據範例2所描述之流程製備,並起始於中間產物15。APCI-MS m/z: 602[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.37(1H,s),8.01(1H,m),7.49(1H,s),7.09(1H,dd),6.12(1H,s),6.05-5.63(2H,m),4.57(1H,bs),4.06(2H,s),3.46(3H,s),3.10-2.96(2H,m),2.77(1H,d),2.54(1H,bs),2.19-1.91(5H,m),1.90-1.77(1H,m),1.67-1.42(2H,m),1.34(3H,s),1.26(1H,d),1.15-1.09(4H,m),1.01(3H,s),0.86(1H,q)。
此化合物係依據範例2所描述之流程製備,並起始於中間產物16。APCI-MS m/z: 625[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.37(1H,s),8.31(1H,s),8.01(1H,m),7.96(1H,s),7.50(1H,s),7.09(1H,dd),6.12(1H,s),6.07-5.60(2H,m),4.64(1H,bs),3.17-3.06(1H,m),3.03(1H,d),2.81(1H,d),2.55(1H,bs),2,28(1H,d),2.22-2.05(3H,m),1.96(1H,m),1.92-1.80(1H,m),1.80-1.69(1H,m),1.59-1.47(1H,m),1.36(3H,s),1.34(1H,s),1.15(1H,d),1.11(3H,d),1.06(3H,s),0.90(1H,q)。
此化合物係依據範例3所描述之流程製備,並起始於中間產物16。APCI-MS m/z: 632[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.37(1H,s),8.31(1H,s),8.01(1H,m),7.96(1H,s),7.50(1H,s),7.09(1H,dd),6.12(1H,s),4.64(1H,bs),3.80(1H,d,AB),3.56(1H,d,AB),3.14-2.99(2H,m),2.81(1H,d),2.55(1H,bs),2.26(1H,d),2.22-2.10(2H,m),2.06(1H,d),1.96(1H,m),1.92-1.80(1H,m),1.79-1.67(1H,m),1.61-1.48(1H,m),1.36(3H,s),1.33(1H,s),1.22(1H,s),1.11(3H,d),1.07(3H,s),0.89(1H,q)。
此化合物係依據範例3所描述之流程製備,並起始於中間產物17。APCI-MS m/z: 605[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.37(1H,s),8.01(1H,m),7.50(1H,s),7.09(1H,dd),6.12(1H,s),4.58(1H,bs),3.78(1H,d,AB),3.56(1H,d,AB),3.02(1H,d),2.96(1H,m),2.77(1H,d),2.54(1H,bs),2.19-2.06(2H,m),2.03-1.91(3H,m),1.90-1.78(1H,m),1.71-1.60(2H,m),1.54-1.41(1H,m),1.35(3H,s),1.27(1H,d),1.16(1H,d),1.12(3H,d),1.08-0.98(5H,m),0.97-0.83(3H,m)。
將中間產物22(0.04 g,0.07mmol)溶於二噁烷(1 mL),得黃色溶液。加入N
-乙基-N
-異丙基丙烷-2-胺(0.03 mL,0.18 mmol)與2-溴乙腈(20 μL,0.03 mmol),並攪拌混合物至隔日。溶液以CH3
CN(1 ml)與水(1 ml)稀釋,隨後注入製備級HPLC管柱(CH3CN/水)。含產物部分經冷凍乾燥,得10 mg希望之產物,為白色固體。APCI-MS m/z: 634[MH+
]。
1
H NMR(400 MHz,DMSO)δ8.40(d,1H),8.17(t,1H),7.57(s,1H),7.35(d,1H),6.25(s,1H),5.34(s,1H),4.53-4.40(m,1H),4.31(s,1H),4.03(dd,2H),3.80(m,2H),3.13(d,1H),2.81(m,1H),2.42-2.13(m,2H),2.10-1.77(m,6H),1.70(m,2H),1.48-1.29(m,5H),0.98(s,3H)。
此化合物係依據範例12所描述之流程製備,並起始於中間產物22與溴氟甲烷。APCI-MS m/z: 632[MH+
]。
1H NMR(400 MHz,DMSO)δ8.40(d,1H),8.15(s,1H),7.62(s,1H),7.36(dd,1H),6.28(s,1H),6.03-5.93(m,1H),5.90-5.80(m,1H),5.30(s,1H),4.47(dd,1H),4.31(s,1H),3.86-3.74(m,2H),3.14(d,1H),2.81(d,2H),2.41-2.13(m,5H),2.11-1.77(m,7H),1.77-1.62(m,1H),1.48-1.27(m,4H),0.95(s,3H)。
此化合物係依據範例12所描述之流程製備,並起始於中間產物22與2-溴乙醇。APCI-MS m/z: 644[MH+
]。
1H NMR(400 MHz,DMSO)δ8.40(d,1H),8.15(d,1H),7.57(s,1H),7.35(dd,1H),6.24(1,1H),5.17(s,1H),4.43(dd,1H),4.28(m,2H),3.87-3.70(m,4H),3.14(d,1H),2.99-2.72(m,4H),2.40-1.95(m,6H),1.94-1.60(m,7H),1.46-1.24(m,4H),0.95(s,3H)。
此化合物係依據範例12所描述之流程製備,並起始於中間產物23與2-溴乙腈。APCI-MS m/z: 639[MH+
]。
1H NMR(400 MHz,DMSO)δ8.40(s,1H),8.15(dd,1H),7.61(s,1H),7.36(dd,1H),6.29(s,1H),5.29(d,1H),4.32(s,1H),4.03(dd,2H),3.89-3.63(m,4H),3.25-3.08(m,2H),2.88-2.71(m,2H),2.42-2.14(m,4H),2.13-1.61(m,7H),1.50-1.28(m,5H),0.92(s,3H)。
可得異構物混合物,且異構物以chiralpak IA管柱(i-己烷/EtOH=1:1)分離,並分析兩尖峰。
上述化合物為chiralpak IA管柱(i-己烷/EtOH=1:1)之第一沖提異構物。APCI-MS m/z: 639[MH+
]。
上述化合物為chiralpak IA管柱(i-己烷/EtOH=1:1)之第二沖提異構物。APCI-MS m/z: 639[MH+
]。
此化合物係依據範例12所描述之流程製備,並起始於中間產物23與溴氟甲烷。APCI-MS m/z: 632[MH+
]。
1H NMR(400 MHz,DMSO)δ8.40(d,1H),8.15(t,1H),7.63(s,1H),7.36(d,1H),6.32(s,1H),6.02-5.94(m,1H),5.89-5.81(m,1H),5.24(d,1H),4.31(s,1H),3.62-3.90(m,4H),3.08-3.26(m,2H),2.71-2.88(m,3H),2.29-2.41(m,2H),1.97-2.14(m,6H),1.78-1.96(m,2H),1.61-1.77(m,1H),1.29-1.48(m,4H),0.90(s,3H)。
可得異構物混合物,且異構物以chiralpak IA管柱(i-己烷/EtOH=1:1)分離,並分析兩尖峰。
上述化合物為chiralpak IA管柱(i-己烷/EtOH=1:1)之第一沖提異構物。APCI-MS m/z: 632[MH+
]。
上述化合物係chiralpak IA管柱(i-己烷/EtOH=1:1)之第二沖提異構物。APCI-MS m/z: 632[MH+
]。
此化合物係依據範例12所描述之流程製備,並起始於中間產物24與2-溴乙腈。APCI-MS m/z: 639[MH+
]。
1H NMR(400 MHz,DMSO)δ8.45(s,1H),8.15(dd,1H),7.66(s,1H),7.36(dd,1H),6.30(s,1H),5.33(s,1H),4.48(dd,1H),4.30(s,1H),4.03(dd,2H),3.83(t,2H),3.14(d,1H),2.82(dd,2H),2.40-2.09(m,6H),2.10-1.61(m,7H),1.50-1.21(m,5H),0.77(s,3H)。
此化合物係製備自中間產物29與2-溴乙醇,並依據範例12所描述之流程製備。所得異構物為Kromasil C18 HPLC管柱二次沖提物。APCI-MS m/z: 625[MH+
]。
1
H NMR(400 MHz,DMSO-d6
)δ7.52(m,2H),7.49(s,1H),7.35(m,2H),6.15(s,1H),4.46(m,2H),4.36(d,1H),3.79(m,2H),3.43(m,2H),2.93(m,3H),2.79(m,1H),2.64(m,1H),2.42(m,1H),2.29(m,1H),2.14(m,3H),2.00-1.70(m,7H),1.58(m,1H),1.34(m,1H),1.22(s,3H),1.11(m,1H)1.00(m,1H),0.86(s,3H). APCI-MS m/z: 625[MH+
]。
此化合物係依據範例12所描述之流程製備,並起始於中間產物30與2-溴乙腈。APCI-MS m/z: 554[MH+
]。
1
H NMR(400 MHz,DMSO)δ8.40(d,1H),8.15(d,1H),7.57(s,1H),7.36(dd,1H),6.25(s,1H),5.24(s,1H),5.02(dd,2H),4.25(d,1H),3.14(d,1H),2.88-2.64(m,2H),2.41-1.99(m,5H),1.82-1.57(m,5H),1.50-1.36(m,2H),1.33(s,3H),0.95(s,3H),0.88-0.75(m,4H)。
此化合物係依據範例12所描述之流程製備,並起始於中間產物31與2-溴乙腈。APCI-MS m/z: 575[MH+
]。
1
H NMR(400 MHz,DMSO)δ8.39(d,1H),8.13(d,,1H),7.54(s,1H),7.35(dd,1H),6.17(s,1H),5.00(dd,2H),4.42(s,1H),4.35(d,1H),2.97(d,1H),2.85-2.58(m,2H),2.46-2.25(m,2H),1.98-1.81(m,3H),1.81-1.56(m,5H),1.49-1.31(m,1H),1.23(s,3H),1.19-0.98(m,2H),0.96-0.76(m,7H)。
此化合物係依據範例2所描述之流程製備,並起始於中間產物32。APCI-MS m/z: 624[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.38(1H,s),8.01(1H,m),7.62(1H,s),7.51(1H,s),7.23(1H,m),7.09(1H,dd),6.55(1H,m),6.13(1H,s),6.09-5.58(2H,m),4.64(1H,bs),3.16-3.00(2H,m),2.82(1H,d),2.55(1H,bs),2.28(1H,d),2.21-2.05(3H,m),1.97(1H,m),1.92-1.80(1H,m),1.80-1.68(1H,m),1.60-1.46(1H,m),1.37(3H,s),1.33(1H,d),1.17-1.13(1H,m),1.12(3H,d),1.06(3H,s),0.90(1H,q)。
此化合物係依據範例3所描述之流程製備,並起始於中間產物32。APCI-MS m/z: 631[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.37(1H,s),8.01(1H,m),7.63(1H,s),7.51(1H,s),7.23(1H,m),7.09(1H,dd),6.55(1H,m),6.12(1H,s),4.64(1H,bs),3.82(1H,d,AB),3.55(1H,d,AB),3.13-3.01(2H,m),2.82(1H,d),2.56(1H,bs),2.25(1H,d),2.21-2.10(2H,m),2.06(1H,d),1.97(1H,m),1.92-1.80(1H,m),1.80-1.67(1H,m),1.59-1.48(1H,m),1.36(3H,s),1.32(1H,d),1.23-1.19(1H,m),1.12(3H,d),1.07(3H,s),0.89(1H,q)。
此化合物係依據範例3所描述之流程製備,並起始於中間產物14。APCI-MS m/z: 593[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.37(1H,s),8.01(1H,m),7.50(1H,s),7.09(1H,dd),6.12(1H,s),4.57(1H,bs),3.79(1H,d,AB),3.56(1H,d,AB),3.06-2.92(2H,m),2.77(1H,d),2.54(1H,bs),2.37(2H,q),2.18-2.06(2H,m),2.03-1.91(3H,m),1.89-1.76(1H,m),1.67-1.55(1H,m),1.54-1.41(1H,m),1.34(3H,s),1.26(1H,d),1.20-1.09(7H,m),1.01(3H,s),0.86(1H,q)。
此化合物係依據範例3所描述之流程製備,並起始於中間產物15。APCI-MS m/z: 609[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.36(1H,s),8.01(1H,m),7.49(1H,s),7.09(1H,dd),6.12(1H,s),4.57(1H,bs),4.06(2H,s),3.79(1H,d,AB),3.58(1H,d,AB),3.46(3H,s),3.07-2.95(2H,m),2.77(1H,d),2.54(1H,bs),2.19-2.00(3H,m),2.00-1.91(2H,m),1.88-1.77(1H,m),1.67-1.43(2H,m),1.34(3H,s),1.25(1H,d),1.17(1H,d),1.12(3H,d),1.02(3H,s),0.86(1H,q)。
此化合物係依據範例2所描述之流程製備,並起始於中間產物17。APCI-MS m/z: 598[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.37(1H,s),8.01(1H,m),7.49(1H,s),7.09(1H,dd),6.12(1H,s),6.05-5.60(2H,m),4.58(1H,bs),3.07-2,93(2H,m),2.77(1H,d),2.54(1H,bs),2.19-2.06(2H,m),2.05-1.90(3H,m),1.90-1.78(1H,m),1.72-1.60(2H,m),1.52-1.40(1H,m),1.34(3H,s),1.27(1H,d),1.16-1.09(4H,m),1.08-0.98(5H,m),0.96-0.83(3H,m)。
此化合物係由中間產物8製備,並依據範例5所描述之流程製備。APCI-MS m/z: 610[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ7.50-7.43(3H,m),7.16(2H,t),6.17(1H,s),4.45(1H,bs),3.72(2H,s),3.40-3.26(2H,m),2.79(1H,d),2.59(1H,t),2.49-2.38(3H,m),2.38-2.18(3H,m),1.94-1.81(2H,m),1.75-1.64(1H,m),1.63-1.51(1H,m),1.40(3H,s),1.38-1.33(2H,m),1.16(3H,t),1.12(3H,s),1.01(3H,d)。
此化合物係由中間產物8製備,並依據範例6所描述之流程製備。APCI-MS m/z: 626[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ7.50-7.42(3H,m),7.16(2H,t),6.18(1H,s),4.46(1H,bs),4.12(2H,s),3.73(2H,s),3.45(3H,s),3.42-3.26(2H,m),2.79(1H,d),2.59(1H,t),2.45-2.18(4H,m),1.95-1.81(2H,m),1.75-1.64(1H,m),1.63-1.51(1H,m),1.40(3H,s),1.39-1.32(2H,m),1.13(3H,s),1.05(3H,d)。
此化合物係由中間產物8製備,並依據範例6所描述之流程製備。APCI-MS m/z: 642[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.25(1H,s),7.94(1H,s),7.50-7.43(3H,m),7.17(2H,t),6.19(1H,s),6.04-5.76(2H,m),4.51(1H,bs),3.56-3.44(1H,m),3.37(1H,d),2.81(1H,d),2.68-2.50(2H,m),2.46-2.25(3H,m),2.01-1.85(2H,m),1.80-1.68(1H,m),1.63-1.51(1H,m),1.42(3H,s),1.39(1H,m),1.33(1H,bs),1.17(3H,s),1.09(3H,d)。
此化合物係由中間產物8製備,並依據範例6所描述之流程製備。APCI-MS m/z: 649[MH+
]。
此化合物係由中間產物5製備,並依據範例1所描述之流程製備。APCI-MS m/z: 627[MH+
]。
1
H NMR(400 MHz,CDCl3
)δ8.36(1H,s),7.99(1H,m),7.51(1H,s),7.07(1H,dd),6.18(1H,s),4.45(1H,bs),4.12(2H,s),3.73(2H,s),3.45(3H,s),3.42-3.27(2H,m),2.81(1H,d),2.61(1H,t),2.44-2.32(2H,m),2.31-2.18(2H,m),1.96-1.82(2H,m),1.75-1.66(1H,m),1.65-1.51(1H,m),1.41(3H,s),1.40-1.34(2H,m),1.13(3H,s),1.05(3H,d)。
本分析係依據Panvera/Invitrogen(外箱產品碼P2893)之市售套組。分析技術為螢光偏極反應。本套組使用重組人類GR(Panvera,外箱產品碼P2812)、FluoromoneTM
標定追蹤劑(GS Red,Panvera,外箱產品碼P2894)以及10X穩定胜肽(Panvera,外箱產品碼P2815)。GR與穩定胜肽試劑保存於-70℃,而GS Red保存於-20℃。套組內亦包括1M DTT(Panvera,外箱產品碼P2325,保存於-20℃)與GR篩選緩衝溶液10X(Panvera,外箱產品碼P2814,最初保存於-70℃,但解凍後則保存於室溫)。避免重複冰凍/解凍所有試劑。GR篩選緩衝溶液10X包含100 mM磷酸鉀、200 mM鉬酸鈉、1 mM EDTA與20% DMSO。
受測化合物(1 μL)與控制組(1 μL)係溶於100%DMSO中,並加入黑色聚苯乙烯384-孔盤(Greiner低容積黑色平底盤,外箱產品碼784076)。0%控制組係為100%DMSO,而100%控制組為10 μM地塞米松(Dexamethasone)。背景溶液(8 μL;分析緩衝液10X、穩定胜肽、DTT與冰冷MQ水)係加入背景培養孔內。除了背景培養孔以外,將GS Red溶液(7 μL;分析緩衝液10X、穩定胜肽、DTT、GS Red與冰冷水)加入所有培養孔內。將GR溶液(7 μL;分析緩衝液10X、穩定胜肽、DTT、GR與冰冷水)加入所有培養孔內。將反應盤密封並於室溫下避光培養2小時。反應盤以Analyst盤讀儀(LJL Biosystems/Molecular Devices Corporation),或其他可紀錄螢光偏極反應(激發波長530 nm、發散波長590 nm,且分光鏡為561 nm)之類似盤讀儀讀取。使用XLfit模型205計算IC50
值,並列於表1。
Claims (7)
- 一種具有下式之化合物:
- 一種醫藥組成物,係包含如申請專利範圍第1項之化合物或其醫藥上可接受之鹽類,並結合一醫藥上可接受之佐劑、稀釋劑或載體。
- 一種醫藥組合物,包含如申請專利範圍第1項之化合物或其醫藥上可接受鹽類、一或多種藥劑,係獨立地選自於:˙選擇性β2 腎上腺素受體協同劑;˙磷酸二酯酶抑制劑;˙蛋白酶抑制劑;˙抗膽鹼激素藥劑;˙趨化激素受體功能調節劑;以及˙激酶功能抑制劑;以及任擇地一或多種醫藥上可接受之賦形劑。
- 一種套組,包含有一第一活性成分製劑,其為如專利範圍第1項之化合物或其醫藥上可接受鹽類,以及一第二 活性成分製劑,其為:˙選擇性β2 腎上腺素受體協同劑;˙磷酸二酯酶抑制劑;˙蛋白酶抑制劑;˙抗膽鹼激素藥劑;˙趨化激素受體功能調節劑;以及˙激酶功能抑制劑;以及用於同時、依序或個別投予該製劑至有需要病患之用藥指示。
- 一種如申請專利範圍第1項之化合物或其在醫藥上可接受之鹽類於製造一藥劑之用途,該藥劑係用於治療氣喘或降低氣喘的風險。
- 一種如申請專利範圍第1項之化合物或其在醫藥上可接受之鹽類於製造一藥劑之用途,該藥劑係用於治療慢性阻塞性肺病或降低慢性阻塞性肺病的風險。
- 一種用於製備如申請專利範圍第2項之醫藥組成物的方法,其包含將如申請專利範圍第1項之化合物或其在醫藥上可接受之鹽類與醫藥上可接受之佐劑、稀釋劑或載體混合。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16632509P | 2009-04-03 | 2009-04-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201040197A TW201040197A (en) | 2010-11-16 |
TWI472533B true TWI472533B (zh) | 2015-02-11 |
Family
ID=42826695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW99110332A TWI472533B (zh) | 2009-04-03 | 2010-04-02 | 新穎化合物 |
Country Status (28)
Country | Link |
---|---|
US (1) | US8338587B2 (zh) |
EP (1) | EP2414377B1 (zh) |
JP (1) | JP5739868B2 (zh) |
KR (1) | KR101599574B1 (zh) |
CN (1) | CN102459305B (zh) |
AR (1) | AR076036A1 (zh) |
AU (1) | AU2010233020B2 (zh) |
BR (1) | BRPI1013380A2 (zh) |
CA (1) | CA2757424A1 (zh) |
CL (1) | CL2011002463A1 (zh) |
CO (1) | CO6420349A2 (zh) |
CR (1) | CR20110519A (zh) |
CU (1) | CU20110185A7 (zh) |
DO (1) | DOP2011000304A (zh) |
EA (1) | EA021342B1 (zh) |
EC (1) | ECSP11011369A (zh) |
ES (1) | ES2568665T3 (zh) |
HN (1) | HN2011002578A (zh) |
IL (1) | IL214982A0 (zh) |
MX (1) | MX2011010208A (zh) |
NI (1) | NI201100176A (zh) |
PE (1) | PE20120644A1 (zh) |
SG (1) | SG174249A1 (zh) |
TW (1) | TWI472533B (zh) |
UA (1) | UA105920C2 (zh) |
UY (1) | UY32520A (zh) |
WO (1) | WO2010114476A1 (zh) |
ZA (1) | ZA201108049B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009044200A1 (en) * | 2007-10-04 | 2009-04-09 | Astrazeneca Ab | Steroidal [3, 2-c] pyrazole compounds, with glucocorticoid activity |
EP2235037A1 (en) * | 2007-12-20 | 2010-10-06 | AstraZeneca AB | Steroid derivatives acting as glucocorticosteroid receptor agonists |
UY32523A (es) * | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticosteroides |
UY32521A (es) * | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Combinación para emplear en el tratamiento de enfermedades respiratorias |
UY32525A (es) * | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticosteroides |
GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
CN104402964B (zh) * | 2014-12-10 | 2016-06-15 | 南京大学 | 闭花木酮的o-(咪唑基)乙基衍生物、制备方法及其用途 |
CN104744556B (zh) * | 2015-04-15 | 2016-06-29 | 马修尧 | 闭花木酮的o-(1h-四氮唑基)乙基衍生物、制备方法及其用途 |
SG11201903209TA (en) | 2016-10-14 | 2019-05-30 | Van Andel Res Institute | Structures and mechanism for the design of highly potent glucocorticoids |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002088167A1 (en) * | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
TW200918047A (en) * | 2007-10-04 | 2009-05-01 | Astrazeneca Ab | Novel compounds |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB933868A (en) | 1958-12-08 | 1963-08-14 | American Cyanamid Co | Process for fluorinating steroids |
US3129218A (en) | 1961-11-01 | 1964-04-14 | Merck & Co Inc | 2-alkoxymethylene steroids of the androstane and pregnane series |
US3072639A (en) | 1962-03-05 | 1963-01-08 | Merck & Co Inc | 16-oxygenated-4-pregneno-[3, 2-c] pyrazoles and process of preparing them |
US3129281A (en) * | 1962-09-25 | 1964-04-14 | George W Hardin | Electric fence insulator and post |
US3364203A (en) | 1965-09-09 | 1968-01-16 | Syntex Corp | 6, 7-methylene and 6, 7-halomethylene pyrazole pregnanes and processes for their preparation |
US3471477A (en) | 1967-10-18 | 1969-10-07 | Syntex Corp | 6-gem-difluoro (3,2-c) and (2,3-d) pyrazole steroids |
DE2727367A1 (de) | 1977-06-14 | 1979-01-04 | Schering Ag | Neue kortikoide |
DE2735110A1 (de) | 1977-08-04 | 1979-02-15 | Hoechst Ag | Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung |
DE2817988A1 (de) | 1978-04-25 | 1979-11-08 | Hoechst Ag | Corticoid 17-alkylcarbonate und verfahren zu deren herstellung |
JPS6067495A (ja) | 1983-09-22 | 1985-04-17 | Ota Seiyaku Kk | ピラゾール誘導体 |
SE8306370D0 (sv) | 1983-11-18 | 1983-11-18 | Draco Ab | Novel androstane-17beta-carboxylic acid esters, a process and intermediates for their preparation, compositions and method for the treatment of inflammatory conditions |
WO1994025478A1 (en) | 1993-04-29 | 1994-11-10 | Instytut Farmaceutyczny | 16α,17α-ACETAL GLUCOCORTICOSTEROIDAL DERIVATIVES |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
IL125686A (en) | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability |
DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-anilinochinazolin derivate |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
CN1431999A (zh) | 2000-05-31 | 2003-07-23 | 阿斯特拉曾尼卡有限公司 | 具有血管损伤活性的吲哚衍生物 |
CN1255391C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管破坏剂的colchinol衍生物 |
MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
GB0110411D0 (en) | 2001-04-27 | 2001-06-20 | Astrazeneca Ab | Chemical process |
ITMI20022606A1 (it) | 2002-12-09 | 2004-06-10 | Farmabios Spa | Processo di sintesi di steroidi polialogenati. |
WO2005028495A1 (en) | 2003-09-24 | 2005-03-31 | Glaxo Group Limited | Anti-inflammatory glucocorticoids |
WO2005063777A1 (en) | 2003-12-23 | 2005-07-14 | Corus Pharma | Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation |
GB0507165D0 (en) | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
WO2007054974A2 (en) | 2005-09-28 | 2007-05-18 | Arch Pharmalab Limited | A green chemistry process for the preparation of pregnadiene esters |
EP2235037A1 (en) | 2007-12-20 | 2010-10-06 | AstraZeneca AB | Steroid derivatives acting as glucocorticosteroid receptor agonists |
PE20091215A1 (es) | 2007-12-21 | 2009-08-14 | Schering Corp | Tioeteres c-21 como agonistas del receptor de glucocorticoides |
MX2010009022A (es) | 2008-02-27 | 2010-09-07 | Astrazeneca Ab | Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso. |
UY32525A (es) | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticosteroides |
UY32521A (es) | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Combinación para emplear en el tratamiento de enfermedades respiratorias |
UY32523A (es) | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticosteroides |
-
2010
- 2010-03-26 UY UY0001032520A patent/UY32520A/es not_active Application Discontinuation
- 2010-03-30 US US12/749,911 patent/US8338587B2/en not_active Expired - Fee Related
- 2010-03-31 AR ARP100101086A patent/AR076036A1/es unknown
- 2010-04-01 JP JP2012503375A patent/JP5739868B2/ja not_active Expired - Fee Related
- 2010-04-01 CN CN201080024580.8A patent/CN102459305B/zh not_active Expired - Fee Related
- 2010-04-01 UA UAA201110628A patent/UA105920C2/uk unknown
- 2010-04-01 ES ES10759128.1T patent/ES2568665T3/es active Active
- 2010-04-01 EP EP10759128.1A patent/EP2414377B1/en active Active
- 2010-04-01 AU AU2010233020A patent/AU2010233020B2/en not_active Ceased
- 2010-04-01 EA EA201190236A patent/EA021342B1/ru not_active IP Right Cessation
- 2010-04-01 PE PE2011001758A patent/PE20120644A1/es not_active Application Discontinuation
- 2010-04-01 MX MX2011010208A patent/MX2011010208A/es not_active Application Discontinuation
- 2010-04-01 KR KR1020117023085A patent/KR101599574B1/ko not_active IP Right Cessation
- 2010-04-01 CA CA2757424A patent/CA2757424A1/en not_active Abandoned
- 2010-04-01 SG SG2011063757A patent/SG174249A1/en unknown
- 2010-04-01 BR BRPI1013380A patent/BRPI1013380A2/pt not_active IP Right Cessation
- 2010-04-01 WO PCT/SE2010/050367 patent/WO2010114476A1/en active Application Filing
- 2010-04-02 TW TW99110332A patent/TWI472533B/zh not_active IP Right Cessation
-
2011
- 2011-09-05 IL IL214982A patent/IL214982A0/en unknown
- 2011-09-08 CO CO11116286A patent/CO6420349A2/es not_active Application Discontinuation
- 2011-09-30 HN HN2011002578A patent/HN2011002578A/es unknown
- 2011-10-03 NI NI201100176A patent/NI201100176A/es unknown
- 2011-10-03 CR CR20110519A patent/CR20110519A/es unknown
- 2011-10-03 CU CU20110185A patent/CU20110185A7/es unknown
- 2011-10-03 DO DO2011000304A patent/DOP2011000304A/es unknown
- 2011-10-03 EC EC2011011369A patent/ECSP11011369A/es unknown
- 2011-10-03 CL CL2011002463A patent/CL2011002463A1/es unknown
- 2011-11-02 ZA ZA2011/08049A patent/ZA201108049B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002088167A1 (en) * | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
TW200918047A (en) * | 2007-10-04 | 2009-05-01 | Astrazeneca Ab | Novel compounds |
Non-Patent Citations (1)
Title |
---|
Chem. Pharm. Bull., 34(4), 1613-1618 Journal of Medicinal Chemistry, 1975, vol. 18, No. 2, 168-172 J. Med. Chem. 2002, 45, 5397-5405 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI472533B (zh) | 新穎化合物 | |
US8163724B2 (en) | Glucocorticosteroids, processes for their preparation, pharmaceutical compositions containing them and their use in therapy | |
US20110294766A1 (en) | 16 Alpha, 17 Alpha-Acetal Glucocorticosteroidal Derivatives and their Use | |
DK2651943T3 (en) | purine derivatives | |
AU2010231954B2 (en) | Novel amide derivatives of steroidal[3,2-c]pyrazole compounds with glucocorticoid activity | |
TW201038589A (en) | Novel compounds | |
CA2707618A1 (en) | Steroid derivatives acting as glucocorticosteroid receptor agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |